# The unwell patient with advanced chronic liver disease: when to use each score?

<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Med</journal-id><journal-title-group><journal-title>BMC Medicine</journal-title></journal-title-group><issn pub-type="epub">1741-7015</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmcid">12239287</article-id><article-id pub-id-type="pmid">40629399</article-id>
<article-id pub-id-type="publisher-id">4185</article-id><article-id pub-id-type="doi">10.1186/s12916-025-04185-w</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>The unwell patient with advanced chronic liver disease: when to use each score?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Moore</surname><given-names>Oliver</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Wai-See</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Read</surname><given-names>Scott</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>George</surname><given-names>Jacob</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ahlenstiel</surname><given-names>Golo</given-names></name><address><email>g.ahlenstiel@westernsydney.edu.au</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03t52dk35</institution-id><institution-id institution-id-type="GRID">grid.1029.a</institution-id><institution-id institution-id-type="ISNI">0000 0000 9939 5719</institution-id><institution>Blacktown Clinical School, School of Medicine, </institution><institution>Western Sydney University, </institution></institution-wrap>Blacktown, NSW Australia </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/017bddy38</institution-id><institution-id institution-id-type="GRID">grid.460687.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0572 7882</institution-id><institution>Blacktown Hospital, Western Sydney Local Health District, </institution></institution-wrap>Blacktown, NSW Australia </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03wtqwa04</institution-id><institution-id institution-id-type="GRID">grid.476921.f</institution-id><institution>Storr Liver Centre, </institution><institution>The Westmead Institute for Medical Research, University of Sydney, </institution></institution-wrap>Westmead, NSW Australia </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04gp5yv64</institution-id><institution-id institution-id-type="GRID">grid.413252.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 0180 6477</institution-id><institution>Westmead Hospital, Western Sydney Local Health District, </institution></institution-wrap>Westmead, NSW Australia </aff></contrib-group><pub-date pub-type="epub"><day>9</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>9</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>23</volume><elocation-id>413</elocation-id><history><date date-type="received"><day>22</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>2</day><month>6</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Prognostication in chronic liver disease and the implementation of appropriate scoring systems is difficult given the variety of clinical manifestations. It is important to understand the limitations of each scoring system as well as the context and patient group from which it was developed to allow appropriate application. This review seeks to explore the optimal clinical uses of different predictive scores developed for compensated and decompensated chronic liver disease, acute on chronic liver failure, and hepatocellular carcinoma. We will also review future areas of research for each score and current gaps in the literature.</p></sec><sec><title>Main body</title><p id="Par2">The Child&#x02013;Pugh score is the pre-eminent prediction score for liver disease that was developed through empiric selection of relevant variables. It is useful for selection of patients for surgical resection of hepatocellular carcinoma but is inferior to other scores for other clinically relevant endpoints such as survival in acute decompensations. The Model for End-Stage Liver Disease (MELD) score and subsequent variants (MELD-Na, MELD 3.0) were developed to predict mortality following elective transjugular intrahepatic portosystemic shunt (TIPS) insertion. An alternative is the Frieberg Index of Post-TIPS Survival (FIPS) score, which has been externally validated for TIPS populations. Organ allocation for liver transplantation is also currently prioritised using the MELD score, with the MELD 3.0 reducing waitlist gender discrepancies. The Chronic Liver Failure Consortium (CLIF-C) acute decompensation (AD) and acute-on-chronic liver failure (ACLF) scores are used for predicting mortality in cirrhotic patients with acute decompensation of liver disease and acute-on-chronic liver failure, respectively. Both scores were developed from retrospective analyses of an observational European cohort with external validation. Understanding of ACLF presentation of advanced liver disease remains in the preliminary stages. Improving collective understanding is important to optimise prognostication. The albumin-bilirubin score is a non-invasive predictor of survival in patients with hepatocellular carcinoma. Incorporating artificial intelligence to personalise predictive algorithms may provide the most effective prognostication for all clinical phenotypes.</p></sec><sec><title>Conclusion</title><p id="Par3">We summarised key prognostic scores used in advanced liver disease and make recommendations for the optimal uses. Nuances in the development and implementation of each are discussed to help guide effective use.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12916-025-04185-w.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Liver</kwd><kwd>Cirrhosis</kwd><kwd>Child&#x02013;Pugh</kwd><kwd>MELD</kwd><kwd>Hepatocellular carcinoma</kwd><kwd>ACLF</kwd><kwd>TIPS</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background
</title><p id="Par31">In the management of chronic liver disease, survival and prognosis are used to guide treatment decisions and discussions with patients and their caregivers. For a clinician, it is important to have appropriate tools to provide an accurate and realistic assessment of the natural course of a patient&#x02019;s disease. Multiple scores have been developed to model survival outcomes in advanced chronic liver disease (ACLD). The first widely utilised score, the Child&#x02013;Pugh score (CPS), remains one of the preeminent models for cirrhosis despite having been developed through empirical selection of relevant variables [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. More recently, contemporary scores have been derived from statistical analysis for variables independently predictive of mortality: the Model for End-Stage Liver Disease (MELD) score has historically represented the most used alternative to the CPS [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. However, the landscape of ACLD has evolved since the development of these scores and will continue to change [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Aetiological causes of ACLD have transitioned from predominantly viral hepatitis to alcoholic-associated liver disease and metabolic dysfunction-associated fatty liver disease (MAFLD) [<xref ref-type="bibr" rid="CR6">6</xref>]. Whilst the optimal diagnostic criteria for steatotic liver disease remain unclear, extended definitions now include patients that may not have been considered to have liver disease when index scores were derived [<xref ref-type="bibr" rid="CR7">7</xref>]. ACLD may also manifest in a variety of phenotypes including acute decompensations&#x000a0;(AD) of ACLD, acute on chronic liver failure (ACLF), stable ACLD in patients awaiting orthotopic liver transplant (OLT) and those with hepatocellular carcinoma (HCC). There are varied outcomes for each of these conditions [<xref ref-type="bibr" rid="CR8">8</xref>]. Moreover, the collective understanding of ACLF is incomplete, with a unifying definition not yet established [<xref ref-type="bibr" rid="CR9">9</xref>]. The advancement of contemporary understanding of ACLD requires re-assessment of prognostic tools. The aim of this review is to summarise, appraise, and compare current scores assessing disease in ACLD and highlight when each may be most useful.
</p></sec><sec id="Sec2"><title>Main text</title><sec id="Sec3"><title>Child&#x02013;Pugh score</title><p id="Par32">In 1964, the CHILD score was developed as a stratification tool for surgical risk in patients with liver cirrhosis. Bilirubin, albumin, ascites size, encephalopathy grade, and nutritional status were empirically selected based on observed association [<xref ref-type="bibr" rid="CR1">1</xref>]. The qualitative variables, ascites, encephalopathy, and nutritional status were each stratified into three groups based on severity, whilst continuous variables, bilirubin, and albumin were stratified by empiric selection of cut-off values. This enabled the manufacturing of a score between 5 and 15 for each patient. However, literature regarding surgical risk during this period did not support malnutrition as an independent predictor of survival [<xref ref-type="bibr" rid="CR10">10</xref>]. The Child&#x02013;Pugh score (CPS) was subsequently proposed in 1973, wherein nutritional status was replaced with prothrombin time [<xref ref-type="bibr" rid="CR11">11</xref>]. On the surface, the score now effectively represented synthetic (albumin, international normalised ratio (INR)) and metabolic (bilirubin, encephalopathy) functions of the liver, with cut-off points for prothrombin time guided by clinical experience. Patients were then able to be distributed across grades of disease (A: 5&#x02013;6, B: 7&#x02013;9, C: 10&#x02013;15) based on their total score from each of the 5 components.</p><p id="Par33">The CPS was the first widely studied score for ACLD [<xref ref-type="bibr" rid="CR2">2</xref>]. It was initially verified for patients being evaluated for surgery for portal hypertension [<xref ref-type="bibr" rid="CR11">11</xref>], with evidence that its use in selecting surgical candidates could be expanded. Small meta-analyses of patients undergoing both elective oesophageal (12 included studies) and pancreatic (8 included studies) resections found that outcomes were better for Child&#x02013;Pugh A patients [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. However, there are no large meta-analyses examining surgical outcomes for patients based on CPS, or indeed validating it as superior to other prognostic scores. Current expert consensus in the American Gastroenterological Association guidelines suggests cautious consideration of its use as part of a pre-surgical risk assessment [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par34">Integration of the CPS, as a measure of compensation status of ACLD, helps refine the Barcelona Clinic Liver Cancer (BCLC) strategy for treatment selection in HCC[<xref ref-type="bibr" rid="CR15">15</xref>]. It has been shown to be useful for guiding patient selection for surgical resection[<xref ref-type="bibr" rid="CR16">16</xref>] and systemic therapy[<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>], as well as established as a predictive factor for mortality following transarterial chemoembolisation (TACE)[<xref ref-type="bibr" rid="CR19">19</xref>]. Recognising the importance of the CPS in making treatment decisions in HCC, a meta-analysis aimed at evaluating first-line treatments for patients with CPS 8 or higher is currently underway (PROSPERO, CRD42024528193).</p><p id="Par35">The CPS score has failed to be validated in several other contexts. Early studies demonstrated that the CPS may have prognostic value in patients with AD [<xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>], however, in a meta-analysis by Wu and colleagues, it did not reach the threshold value for predicting mortality (<italic>p</italic>&#x02009;= 0.28) [<xref ref-type="bibr" rid="CR24">24</xref>]. 16 studies were incorporated from countries across Europe, South America, and Asia attempting to predict mortality outcomes following hospitalisation for AD, but significance was not met. Similarly, it has not demonstrated good discriminatory capacity for patients with ACLF [<xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>]. A meta-analysis by Zheng and colleagues showed that the CPS performed worst out of all considered scores, with an AUROC of 0.71 across 16 studies considered [<xref ref-type="bibr" rid="CR28">28</xref>]. Further, whilst a retrospective study by Pohl and colleagues suggested its use in post-transjugular intrahepatic portosystemic shunt (TIPS) mortality [<xref ref-type="bibr" rid="CR29">29</xref>], meta-analysis finds it non-superior to the MELD score [<xref ref-type="bibr" rid="CR30">30</xref>]. There are currently two registered meta-analyses designed to assess predictive factors for survival post-TIPS, of which CPS is considered a variable (PROSPERO, CRD420251007253, and CRD42024502288).</p><p id="Par36">The intrinsic advantage of the CPS is that it is easy to interpret through the provision of distinct risk groups. When compared to other continuous scores, it provides a simple and clear output that is useful for conveying information to patients that can be translated into overall survival (Additional File 1: Table S1) [<xref ref-type="bibr" rid="CR3">3</xref>]. Each variable has also been shown to be an independent predictor of mortality. D&#x02019;Amico and colleagues conducted a systematic review to identify significant predictors of survival in cirrhosis. Across 118 studies, the most common were the five variables in the CPS as well as the score itself and age [<xref ref-type="bibr" rid="CR2">2</xref>]. A recent meta-analysis of biochemical predictors of decompensation in ACLD by Gananandan and colleagues validates that INR, albumin, and bilirubin are independent predictors [<xref ref-type="bibr" rid="CR31">31</xref>]. However, whilst univariate models can identify clinical parameters as independent predictors of survival, multivariate analysis is required to confirm that when combined, they all still have an independent impact [<xref ref-type="bibr" rid="CR32">32</xref>]. Given the complex interactions between various organs for synthesis and metabolism, expert opinion suggests the CPS is more appropriate as a multiorgan assessment in patients with ACLD rather than a reflection of liver function [<xref ref-type="bibr" rid="CR3">3</xref>]. A retrospective audit of 1080 patients by Charif and colleagues demonstrated that whilst all elements were predictors in univariate analysis, they did not remain independent predictors when incorporated into multivariate analysis [<xref ref-type="bibr" rid="CR33">33</xref>]. The other limitation of empirically selecting variables is that other important predictors of survival may be omitted. It is now well understood that renal function [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>] and hyponatremia [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>] are important predictors of survival, neither of which are accounted for by the CPS. These biochemical abnormalities are characteristic of the hyperdynamic circulatory phenotype of portal hypertension, a key pathological process that the CPS does not consider [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Simplifying the range of scores to 10 (across 3 grades) limits how discriminatory it can be. The conversion of continuous variables to categorical groups may achieve greater simplicity, but it is at the loss of statistical power and makes the score more susceptible to confounders [<xref ref-type="bibr" rid="CR40">40</xref>]. Ultimately, despite being the index score developed in the field, clinical applicability remains limited.</p></sec><sec id="Sec4"><title>MELD score and subsequent variants (MELD-Na, MELD 3.0)</title><p id="Par37">With the development and increasing utilisation of novel rescue procedures to manage bleeding oesophageal varices, the MELD score was developed in 2000 to predict 3-month mortality following TIPS insertion [<xref ref-type="bibr" rid="CR41">41</xref>]. The initial score was developed in a retrospective cohort of 231 patients undergoing elective TIPS insertion between 1991 and 1995. The study excluded those with severe cardiopulmonary or intrinsic renal disease, whilst OLT was not considered a disease endpoint, which may lead to observation bias. The derivation study internally verified the MELD scores&#x02019; capacity to predict mortality in patients following TIPS insertion [<xref ref-type="bibr" rid="CR41">41</xref>], which was quickly expanded to patient selection for liver transplantation (Additional File 1: Table S2) [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>].</p><p id="Par38">The combination of serum sodium level and MELD score soon became of interest given that hyponatremia is an independent predictor of risk of complications following liver transplantation [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. Kim and colleagues retrospectively analysed a cohort of liver transplant patients in order to determine the predictive ability of the MELD score and the MELD score plus sodium for 3-month mortality (Additional File 1: Table S3) [<xref ref-type="bibr" rid="CR37">37</xref>]. From 2016, the MELD-Na score was adopted by UNOS for deceased donor liver allocation [<xref ref-type="bibr" rid="CR46">46</xref>]. Objectivity, however, was not pursuant to the implementation of the MELD or MELD-Na scores for donor allocation as there were higher rates of waitlist mortality in female patients [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. The MELD score predicts lower overall mortality in female patients, possibly due to reduced creatinine production [<xref ref-type="bibr" rid="CR49">49</xref>]. Kim and colleagues again used a large cohort of 29,410 waitlist candidates to amend the MELD score, re-weighing the importance of creatinine whilst introducing albumin and sex as covariates in the MELD 3.0 [<xref ref-type="bibr" rid="CR50">50</xref>]. The derivation cohort demonstrated re-stratification of 8.8% of patients to a higher score, thereby increasing the effectiveness of organ allocation with improved discrimination in comparison to MELD-Na (concordance statistic 0.869 vs. 0.862, <italic>p</italic>&#x02009;&#x0003c; 0.01). It has been adopted as the current allocation standard by UNOS whilst European guidelines support its use [<xref ref-type="bibr" rid="CR51">51</xref>]. An external retrospective study engaging 6071 transplant candidates identified that female sex is not an independent predictor when incorporated into Cox regression analysis with the MELD 3.0 [<xref ref-type="bibr" rid="CR52">52</xref>]. Whilst it was powered to detect significant differences, the design does not effectively test the impact of the MELD 3.0 and prospective studies are needed to assess whether it truly accounts for gender discrepancies.</p><p id="Par39">The MELD 3.0 has been externally validated by retrospective studies in Korea and Singapore for mortality prediction for inpatients with cirrhosis. Both studies demonstrated better discrimination compared to prior iterations at 3 and 6 months [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. A 2018 meta-analysis by Wu and colleagues demonstrated that the MELD score met the threshold value for significance in predicting mortality for patients with AD at 3 (<italic>p</italic>&#x02009;= 0.010) but not 6 (<italic>p</italic>&#x02009;= 0.760) or 12 months (<italic>p</italic>&#x02009;= 0.139) [<xref ref-type="bibr" rid="CR24">24</xref>]. Subgroup analysis found that across 4 studies the MELD score was significant in predicting mortality following an upper gastrointestinal (GI) bleed (<italic>p</italic>&#x02009;&#x0003c; 0.001). A systematic review by D&#x02019;Amico and colleagues assessing the MELD score&#x02019;s ability to predict all-cause mortality for patients with cirrhosis is currently underway [<xref ref-type="bibr" rid="CR55">55</xref>]. Secondary outcomes of all-cause mortality for patients with TIPS, alcoholic liver disease or OLT are also being examined.</p><p id="Par40">There are other potential uses for the MELD score. Guidelines still support the use of the MELD score as a tool to grade the severity of alcoholic hepatitis, with the STOPAH trial showing superiority to Maddrey&#x02019;s discriminant function [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. A registered trial by Tschaen and colleagues is underway performing a meta-analysis to compare the two (PROSPERO, CRD42024562395). A small meta-analysis of 5 studies did not find a statistical relationship between MELD score and mortality in MAFLD patients undergoing OLT; however, it was the opinion of the authors that, based on qualitative findings, a higher score conveys worse prognosis [<xref ref-type="bibr" rid="CR58">58</xref>]. The BOMASH trial (Clinical trial ID: NCT06813508) is a prospective analysis attempting to establish predictive factors for OLT and HCC in patients with MAFLD that may help establish this relationship.</p><p id="Par41">The intrinsic strengths of the MELD scores come from their objective construction as a product of multivariate analysis, representing the best method to minimise confounders and increase statistical power [<xref ref-type="bibr" rid="CR32">32</xref>]. Being continuous scores, they also possess higher statistical power [<xref ref-type="bibr" rid="CR59">59</xref>]. The MELD scores are also independent of disease aetiology and decompensated sequelae (ascites, HE, acute variceal bleeding). The increasing burden of metabolic associated fatty liver disease and the decreasing incidence of ACLD due to hepatitis B virus (HBV) and hepatitis C virus (HCV) infection indicates that the dominant liver disease aetiologies have changed, and disease courses are likely to be different[<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. As the MELD score is not affected by disease aetiology, it is more resistant to the changing etiological landscape of liver disease [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>].</p><p id="Par42">Whilst the components of the MELD scores are independent predictors of mortality, each may have varied significance due to the maladaptive neurohormonal and physiological responses in ACLD. Rosenstengle and colleagues conducted a large analysis of transplant-listed candidates, stratifying them by dominant biochemical parameter: bilirubin (MELD-Br, <italic>n</italic>&#x02009;= 13,658), INR (MELD-INR, <italic>n</italic>&#x02009;= 13,809), and creatinine (MELD-Cr, <italic>n</italic>&#x02009;= 12,412). Survival was lower for females across each group, emphasising the importance of prospectively validating the MELD 3.0 score, whilst the MELD-Cr had significantly lower 1-year intention-toto-treat rates (<italic>p</italic>&#x02009;&#x0003c; 0.001) [<xref ref-type="bibr" rid="CR62">62</xref>]. Creatinine is a variable that may be affected by many patient-specific characteristics including sarcopenia and myosteatosis, which are themselves independent predictors of survival [<xref ref-type="bibr" rid="CR63">63</xref>]. Lattanzi and colleagues demonstrated in a prospective trial of 249 cirrhotics that radiologically identified sarcopenia and myosteatosis were independently associated with mortality, and that amalgamating them with the MELD score resulted in improved prediction of 3- and 6-month mortality [<xref ref-type="bibr" rid="CR64">64</xref>]. Meta-analyses have supported the prognostic importance of sarcopenia [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]. The limitations of each variable in the MELD scores including hyponatremia are further discussed in the supplement.</p><p id="Par43">The initial proposed MELD-Na score by Biggins and colleagues prioritised lower sodium cut-off values (120 mmol/L to 135 mmol/L) than the widely accepted score later proposed by Kim and colleagues (125 mmol/L to 140 mmol/L) [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]. The perennial challenge of donor allocation is balancing the dichotomy between transplant list dropout and post-operative mortality. Allocations using the lower values may result in the capture of more vulnerable patients, with hyponatremia conferring increased waitlist mortality; however, it also has post-operative risks, most prevalently the risk of osmotic demyelination syndrome. Dawwas and colleagues conducted a retrospective study of 5150 patients demonstrating that hyponatremia (sodium &#x0003c;&#x02009;130 mmol/L) was associated with a 55% increased 3-month mortality following OLT [<xref ref-type="bibr" rid="CR68">68</xref>]. Prioritisation discrepancies between the two approaches need refinement to balance waitlist mortality with transplant complications effectively.</p></sec><sec id="Sec5"><title>United Kingdom End-Stage Liver Disease (UKELD) score</title><p id="Par44">Around the same time as the development of the MELD-Na score, Barber and colleagues aimed to produce a prognostic score for allocation of liver transplantation in a population specific to the United Kingdom (UK). From a cohort of 1103 patients awaiting liver transplantation at 7 centres across the UK, statistical analysis was conducted using Cox regressions to identify bilirubin, INR, and sodium as independent predictors of survival[<xref ref-type="bibr" rid="CR69">69</xref>]. Creatinine was empirically included as a variable in the development of a predictive score, which was validated in a prospectively recruited cohort of 452 patients. The derivation study found the UKELD to be a superior predictor of mortality for patients on the transplant list when compared to the MELD and MELD-Na scores. In 2008, the UKELD score was incorporated into the UK guidelines for the allocation of liver transplants, with a score &#x02265;&#x02009;49 established as the cut-off for transplant eligibility, as this equated to an equal risk of mortality (Additional File 1: Table S4) [<xref ref-type="bibr" rid="CR70">70</xref>]. It currently remains an important part of the allocation process in determining survival on the wait list; however, donor allocation has largely been replaced by a more nuanced scheme designed to maximise transplant benefit [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. The Gender Equity Model for Liver Allocation (GEMA) score was also developed from 5762 patients on the UK transplant registry to enable equitable organ allocation. It was internally validated in 1920 Australian transplant patients and externally in 6071 Spanish patients [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]. Whilst guidelines consider its use, it has not been widely adopted [<xref ref-type="bibr" rid="CR51">51</xref>].</p><p id="Par45">An ideal score for liver transplantation should allocate patients on the wait list with the goal of minimising mortality and maximising survival post-transplant, the latter of which is not accounted for by the UKELD score [<xref ref-type="bibr" rid="CR74">74</xref>]. Although the UKELD is employed as a score for stratifying patients for donor allocation, it does not have any prognostic capacity for survival following transplantation [<xref ref-type="bibr" rid="CR69">69</xref>]. By contrast, the MELD score has been shown to be inversely related to post-transplantation mortality [<xref ref-type="bibr" rid="CR75">75</xref>], most analysis is low-level evidence [<xref ref-type="bibr" rid="CR76">76</xref>]. Further investigation is required.</p></sec><sec id="Sec6"><title>CLIF-C ACLF score</title><p id="Par46">Acute on chronic liver failure (ACLF) is a clinical syndrome characterised by the development of multiorgan failure in the context of liver cirrhosis [<xref ref-type="bibr" rid="CR77">77</xref>]. It is a unique variant of AD associated with high short-term mortality [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR77">77</xref>]. The CANONIC study is a prospective, multi-centre European observational study of 1349 AD patients that helped establish the definition of, and ultimately predictive algorithms for, ACLF. Nearly two thirds of the chronic liver failure (CLIF) consortium derived cohort had aetiology relating to alcohol intake [<xref ref-type="bibr" rid="CR77">77</xref>]. In addition to the presence of AD and high 28-day mortality rate (15%), organ failure measured by sepsis organ failure assessment (SOFA) was required for a diagnosis of ACLF. The SOFA score (comprising liver, kidney, brain, coagulation, circulatory and respiratory system failure) was consensus developed for population-level assessments of mortality in intensive care unit patients but was subsequently accepted at the individual level for evaluation of sepsis [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR79">79</xref>]. The use of the SOFA score to define outcomes in clinical trials is acceptable as a measure of organ failure, and the authors increased the validity by reporting sub-scores for each type of organ failure [<xref ref-type="bibr" rid="CR80">80</xref>].</p><p id="Par47">Given the empirical approach to derivation, it was of interest if other predictive values could improve the discriminatory performance of the index SOFA-based clinical score (titled CLIF-OF score, Additional File 1: Table S5). Jalan and colleagues performed a retrospective regression analysis on 275 CANONIC patients with ACLF to incorporate CLIF-OF parameters with additional white cell count (WCC) and age parameters in a newly derived CLIF-C ACLF score. Internal validation in a prospective cohort of 225 French ACLF patients showed superiority to MELD, MELD-Na, and Child&#x02013;Pugh scores for 28- and 90-day mortality [<xref ref-type="bibr" rid="CR81">81</xref>]. A retrospective study of 74,790 patients from the Veteran&#x02019;s health administration in America confirmed the improved discrimination capability of the CLIF-C ACLF score[<xref ref-type="bibr" rid="CR82">82</xref>]. However, discrepancies between definitions of ACLF persist across geographical regions, with the Asian Pacific Association for Study of the Liver (APASL) including cut-off variables for bilirubin and INR as a requirement for diagnosis [<xref ref-type="bibr" rid="CR83">83</xref>]. A meta-analysis examining 23 studies from Asian countries (total 26 studies; 3672/4732 patients from Asian countries; 77.60%) suggested that MELD (AUROC 0.82) was superior to the CLIF-SOFA score (AUROC 0.73) [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR84">84</xref>]. Further, a study of 18,416 UNOS transplant candidates with ACLF found that a combination of MELD score and ACLF grade showed excellent calibration (goodness of fit <italic>p</italic>&#x02009;= 0.98) and correlation (<italic>R</italic>&#x02009;= 0.99) for waitlist mortality[<xref ref-type="bibr" rid="CR85">85</xref>]. A retrospective study of 433 patients using the APASL definition found that a score incorporating sarcopenia and MELD score had an AUROC of 0.86, but no comparison to the CLIF-C ACLF score was made [<xref ref-type="bibr" rid="CR86">86</xref>]. Establishing a unified definition and further prospective studies are needed. There are currently two prospective, observational studies underway in China (NCT05393453) and India (NCT06069284) designed to identify predictors of mortality in ACLF.</p><p id="Par48">Nearly two thirds of the cohort from the derivation study had an aetiology relating but not limited to alcohol, whilst excessive alcohol intake has been identified as one of the main triggers of ACLF [<xref ref-type="bibr" rid="CR77">77</xref>]. Systemic inflammation is over-represented in patients with alcoholic ACLF [<xref ref-type="bibr" rid="CR87">87</xref>]. The CLIF-C ACLF score, and the selection of WCC as a variable, may only be optimal for measuring mortality in patients with alcohol-related disease. However, a subsequent study by Li and colleagues identified the CLIF-C ACLF score maintains its predictive capacity in patients with hepatitis B virus [<xref ref-type="bibr" rid="CR88">88</xref>]. Further research should be conducted based on etiological sub-groups to confirm that patients with alcoholic ACLF are being fully accounted for.</p></sec><sec id="Sec7"><title>CLIF-C AD score</title><p id="Par49">Following the success of the CLIF-C ACLF score, the CLIF consortium became interested in developing a score for AD without ACLF. Regression analysis was run on 1016 CANONIC study patients without ACLF, identifying age, creatinine, INR, WCC, and sodium as characteristics associated with mortality at 90, 180, and 365 days [<xref ref-type="bibr" rid="CR89">89</xref>]. The derivation study externally verified the superiority of the CLIF-C AD in predicting 90-day mortality (AUROC 0.76) compared to the CPS (AUROC 0.65, <italic>p</italic>&#x02009;&#x0003c; 0.001), MELD (AUROC 0.66, <italic>p</italic>&#x02009;&#x0003c; 0.001), and MELD-Na (AUROC 0.70, <italic>p</italic>&#x02009;= 0.024) scores. It is used primarily for predicting survival in hospitalised patients with an acute decompensation of cirrhosis [<xref ref-type="bibr" rid="CR90">90</xref>]. It has also been shown to be superior to the CPS, MELD, and albumin-vilirubin (ALBI) scores for patients undergoing TIPS insertion, but not the MELD-Na score [<xref ref-type="bibr" rid="CR91">91</xref>].</p><p id="Par50">The scores used to measure mortality in AD we have previously discussed were developed without excluding patients with ACLF. It is possible that patients with ACLF may have skewed mortality statistics given their high rates of short-term mortality [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR77">77</xref>]. Furthermore, the CLIF-C AD score was developed measuring survival as the primary outcome in patients being hospitalised for AD. Other scores such as the CPS and MELD score were developed in different contexts and later verified for use in predicting survival. The CLIF-C AD score is the first major score we are aware of that was developed for survival in patients with AD. Unlike the development of previous scores, the authors sub-distributed liver transplantation as a competing risk to mortality during derivation. This enabled the study to adjust for the effect of liver transplantation, therefore replicating real-life situations where a patient&#x02019;s future chance of transplant may not be known. However, when competing risks are used, the one-to-one correspondence between hazard and cumulative incidence (i.e. between risk and rate) is lost [<xref ref-type="bibr" rid="CR92">92</xref>]. The variables selected through regression analysis may not be as strongly associated with mortality as the analysis suggests.</p><p id="Par51">The CLIF-C AD score stratifies patients into high (&#x0003e; 60) and low (&#x0003c; 45) risk groups. However, patients with a score between 45 and 60 do not qualify for either risk group. The main advantage of a score that stratifies risk groups is its ability to simply convey prognostic information to patients. In the derivation study, 57% of the participants did not qualify for a risk group, indicating there is a significant proportion of patients who are provided little prognostic information from the CLIF-C AD score. Further research into quantifying the risk of these intermediate patients should be conducted to increase the value of the CLIF-C AD score.</p><p id="Par52">Whilst the MELD score imposes a minimum value for the number of points that can be assigned to a patient&#x02019;s score when they are on dialysis, the CLIF-C AD score does not take this into consideration. Patients that are on regular haemodialysis therapy may have erroneously low scores due to a low creatinine level, despite a higher disease burden. ACLD is common in dialysis patients, and as such this represents a significant sub-population for whom the CLIF-C AD score may overestimate survival [<xref ref-type="bibr" rid="CR93">93</xref>].</p><p id="Par53">A similarly novel score for mortality prediction in cirrhosis, the modified Liaoning score, was recently developed in a prospective enrolled cohort of 474 patients in China [<xref ref-type="bibr" rid="CR94">94</xref>]. Utilising age, ascites, presence of upper GI bleed, platelet count, bilirubin, albumin, and creatinine, the score was validated in three prospective cohorts from Fuzhou, China (AUROC 0.881); Jinan, China (AUROC 0.722); and Brazil (AUROC 0.759) for 2-year survival, with each having numerically higher AUROCs than the MELD and CPS. Prospective studies comparing new predictive scores such as the CLIF-C AD, MELD 3.0, and modified Liaoning scores to contemporary ones such as the MELD and Child&#x02013;Pugh are indicated.</p></sec><sec id="Sec8"><title>Albumin-bilirubin (ALBI) score</title><p id="Par54">HCC is a common endpoint for patients with chronic liver disease, with prognosis determined by tumour burden and underlying liver function. The tumour-node-metastases (TNM) staging system is well established in predicting survival in patients based on tumour burden [<xref ref-type="bibr" rid="CR95">95</xref>], underlying liver function has historically been arbitrarily assessed using the CPS. Johnson and colleagues determined to develop a model that predicted mortality in HCC patients specifically focusing on the impact of liver function on survival [<xref ref-type="bibr" rid="CR96">96</xref>].</p><p id="Par55">Patients for the study were recruited from major HCC centres in Japan, Hong Kong, Spain, England, and the USA, with all patients having advanced disease by Barcelona Clinic Liver Cancer (BCLC) staging and being treated with sorafenib. Univariate analysis was conducted on the Japanese cohort as this was the largest and most complete database. Independent predictors of mortality were male sex, log<sub>10</sub>(bilirubin), albumin, tumour size, tumour number, the presence of vascular invasion, and TNM stage. TNM staging and tumour size are more representative of tumour burden rather than underlying liver function. When these were removed from the model, the variables that remained consistently associated with survival were log<sub>10</sub>(bilirubin), albumin, vascular invasion, and tumour number. The latter two were adjudged to be more correlated with tumour burden than underlying liver function, and as such, log<sub>10</sub>(bilirubin) and albumin were elected as the variables. Cox regression linear predictors were used to determine three grades of the ALBI score: &#x02264; &#x02212; 2.60 (ALBI grade 1), &#x0003e; &#x02212; 2.60 to &#x02264; &#x02212; 1.39 (ALBI grade 2), and &#x0003e; &#x02212; 1.39 (ALBI grade 3). The study then validated the ALBI score in the cohorts of patients from other centres to show that it retained its discriminatory ability.</p><p id="Par56">In contrast to the specific patient population selected for the derivation study, HCC encompasses a heterogenous population, perhaps weakening the versatility of the ALBI score. It has been validated as a predictor of survival in patients with advanced HCC (Additional File 1: Table S6) [<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR97">97</xref>] and expanded to patients with all levels of BCLC staging and in palliative conditions [<xref ref-type="bibr" rid="CR98">98</xref>, <xref ref-type="bibr" rid="CR99">99</xref>]. Guidelines currently recommend the use of atezolizumab and bevacizumab as first-line therapy for patients with advanced HCC, with a post-HOC analysis of 336 patients from the foundational phase III IMBrave150 study finding progression-free survival was lower for grade 2 patients (5.6 months (95% CI, 5.3, 7.0)) compared to grade 1 patients (8.8 months (95% CI: 6.7, 10.0)) treated with atezolizumab/bevacizumab [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR100">100</xref>]. Eight studies (6538 patients) were included in a meta-analysis by Mishra and colleagues that found pre-treatment ALBI grade corresponded with mortality outcomes following transarterial chemoemobilisation [<xref ref-type="bibr" rid="CR101">101</xref>].</p><p id="Par57">A meta-analysis comprising 5 Chinese and 2 Italian cohort studies of predominantly viral HCC with cirrhosis (5377 patients; 90.3&#x02013;100% Child&#x02013;Pugh A) found that ALBI grade 2 and 3 patients had a 2.572-fold (95% CI, 1.825 to 3.626, <italic>p</italic>&#x02009;&#x0003c; 0.001) higher chance of post-hepatectomy liver failure when compared to grade 1 patients [<xref ref-type="bibr" rid="CR102">102</xref>]. It may be a useful tool to augment risk stratification prior to surgery in Child&#x02013;Pugh A patients.</p><p id="Par58">The ABLI score utilises two variables in its prediction of mortality risk&#x02014;albumin and bilirubin. Albumin levels can be influenced by therapeutic interventions such as paracentesis and albumin infusions [<xref ref-type="bibr" rid="CR103">103</xref>, <xref ref-type="bibr" rid="CR104">104</xref>]. With simple interventions, half the variables in the ALBI score may be altered, resulting in significantly altered survival predictions. Continually, there are many independent predictors for survival, such as renal function, which are not accounted for by the ALBI score.</p></sec><sec id="Sec9"><title>Frieberg Index of Post-TIPS Survival (FIPS) score</title><p id="Par59">Transjugular intrahepatic portosystemic stent (TIPS) is a non-surgical therapy utilised in patients with portosystemic hypertension suffering from recurrent ascites or secondary prophylaxis of variceal bleeding [<xref ref-type="bibr" rid="CR105">105</xref>]. The MELD score was initially developed for post-TIPS survival whilst the CPS has also been validated in this context [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR106">106</xref>]. Since the introduction of these scores however, developments such as the expanding polytetrafluoroethylene-covered stent grafts (ePTFE-SGs) has resulted in higher survival rates and fewer complications [<xref ref-type="bibr" rid="CR107">107</xref>]. With consideration of these differences, a retrospective German cohort of 835 patients was used to examine the evolution in indications for TIPS insertion. When the MELD score was first developed most patients underwent TIPS as an emergency procedure for variceal bleeding, however in contemporary practice the main indication is diuretic resistant ascites [<xref ref-type="bibr" rid="CR108">108</xref>]. In 2021, Bettinger and colleagues retrospectively developed the Freiberg Index of Post-TIPS Survival (FIPS) from a German cohort of 1871 patients with de novo TIPS insertion, to better characterise short term post-TIPS mortality risk [<xref ref-type="bibr" rid="CR109">109</xref>]. Multivariate regression determined age, the logarithm of bilirubin, albumin, the inverse of creatinine and pre-procedure history of hepatic encephalopathy to be the most salient prognostic variables. A high and low risk group, stratified by the 85th percentile, showed distinctly different overall survival on Kaplan&#x02013;Meier analysis. External validation has occurred in large retrospective cohorts from America and China [<xref ref-type="bibr" rid="CR110">110</xref>, <xref ref-type="bibr" rid="CR111">111</xref>]. However, a recent meta-analysis by Zhao and colleagues confirmed the MELD score to be consistently the best predictor of short term survival (AUROC 0.72 for 3 month survival); in particular a prospectively collected Chinese cohort of 855 patients demonstrated the MELD 3.0 to be superior for 3 month mortality (AUROC 0.727 vs 0.582 for FIPS, <italic>p</italic>&#x02009;= 0.015) [<xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR113">113</xref>]. Zhao&#x02019;s meta-analysis demonstrated the FIPS score had an AUROC of 0.75 for overall transplant free survival; however, the Bettinger&#x02019;s initial derivation study did not have enough statistical power to determine whether it was predictive of liver transplantation in post-TIPS patients.</p><p id="Par60">The derivation study had no control group assigned to help identify which patients may benefit from TIPS insertion based on the FIPS score. Alternative therapies for recurrent ascites and secondary prophylaxis of variceal bleeding are available to patients, and it is important to differentiate clinically who would benefit from TIPS instead of these. Stockhoff and colleagues performed retrospective propensity score matching on 784 German patients to compare treatment with TIPS (<italic>n</italic>&#x02009;= 256) and paracentesis (<italic>n</italic>&#x02009;= 528). In the low-risk FIPS group, there was significantly better survival when treated with TIPS compared to paracentesis (<italic>p</italic>&#x02009;= 0.037), no difference was apparent in the high-risk group (<italic>p</italic>&#x02009;= 0.557) [<xref ref-type="bibr" rid="CR114">114</xref>]. The conclusion drawn by the authors was that high-risk FIPS grouping should not preclude TIPS insertion; however, further analysis into the ability of the FIPS score to provide clinical information beyond prognosis should be pursued.</p><p id="Par61">Given the clinical parameters of bilirubin, albumin, creatinine, and age are all known to be associated with decompensated liver disease, the FIPS score also has since been shown to predict mortality in patients with acute decompensation of ACLD [<xref ref-type="bibr" rid="CR114">114</xref>, <xref ref-type="bibr" rid="CR115">115</xref>]. Inclusion in future meta-analyses would be beneficial.</p></sec></sec><sec id="Sec10"><title>Conclusions</title><p id="Par62">The use of statistical analysis to assess prognosis has resulted in the development of multiple scores measuring mortality and prognostic outcomes in ACLD. Table <xref rid="Tab1" ref-type="table">1</xref> represents possible clinical scenarios and the recommended score to use. Alternatives are provided but should be used cautiously. The possible use of each score is represented in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref><italic>.</italic> For patients with cirrhosis, the CLIF-C AD and CLIF-C ACLF scores are indicated to predict mortality for their respective clinical scenarios. The MELD 3.0 score is the optimal score for allocation of patients for liver transplant in those patients with cirrhosis and HCC. For patients with diagnosed HCC, the CPS is useful for selecting patients for surgical resection while the ALBI is a non-invasive predictor of survival. The FIPS score may be a useful adjunct for survival estimation following TIPS insertion. Mortality following TIPS insertion is best assessed through the MELD 3.0 score.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Clinical presentations with optimal (bold) and alternative (italics) scores that may be used</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Clinical situation for patients with ACLD</th></tr></thead><tbody><tr><td align="left"><p>Pre-surgical risk assessment</p><p><bold>Child&#x02013;Pugh</bold></p></td></tr><tr><td align="left"><p>Stratifying treatment selection in HCC</p><p><bold>Child&#x02013;Pugh</bold> (as part of BCLC recommendations)</p><p><italic>ALBI Grade</italic></p></td></tr><tr><td align="left"><p>Mortality following TIPS insertion</p><p><bold>MELD 3.0</bold></p><p><italic>MELD, MELD-Na, FIPS, CLIF-C AD</italic></p><p>Prioritisation of candidates for liver transplantation</p><p><bold>MELD 3.0</bold></p><p><italic>MELD, MELD-Na, UKELD, GEMA</italic></p></td></tr><tr><td align="left"><p>Mortality following acute decompensation</p><p><bold>CLIF-C AD</bold></p><p><italic>Modified Liaoning score, FIPS</italic></p></td></tr><tr><td align="left"><p>Mortality in ACLF</p><p><bold>CLIF-C ACLF</bold></p><p><italic>MELD, MELD with ACLF grade</italic></p></td></tr><tr><td align="left"><p>Mortality risk in patients with HCC</p><p><bold>ALBI Grade</bold></p><p>Outcomes in alcoholic hepatitis</p><p><bold>MELD</bold></p><p><italic>Maddrey&#x02019;s discriminant function</italic></p></td></tr></tbody></table></table-wrap><fig id="Fig1"><label>Fig. 1</label><caption><p>Possible clinical contexts under which each reviewed score may be considered for use</p></caption><graphic xlink:href="12916_2025_4185_Fig1_HTML" id="MO1"/></fig></p><p id="Par63">We have outlined the strengths and weaknesses (Table <xref rid="Tab2" ref-type="table">2</xref>) of each scoring system. Although most scores employ the use of independent predictors, they are weakened by the susceptibility of individual variables to alteration. Interactions with other variables and therapeutic interventions all contribute to their malleability. For example, creatinine is influenced by a range of factors, such as age, muscle mass, and dietary protein intake, with sarcopenia being particularly prevalent in ACLD [<xref ref-type="bibr" rid="CR116">116</xref>, <xref ref-type="bibr" rid="CR117">117</xref>]. These factors, particularly sarcopenia and myosteatosis, are not accounted for by current scores. It has been shown that the MELD score underestimates mortality in patients with renal disease and it would not be unreasonable to expect similar results with other scores [<xref ref-type="bibr" rid="CR118">118</xref>]. Continually, therapeutic interventions such as diuretics or large volume paracentesis can cause short-term variations in creatinine and albumin levels. These fluctuations result in a changed MELD score despite the risk of death being unchanged [<xref ref-type="bibr" rid="CR119">119</xref>]. Hypoalbuminemia is also associated with high INR [<xref ref-type="bibr" rid="CR120">120</xref>]. There is a risk of valuing synthetic capacity at double the other parameters in scores such as the CPS [<xref ref-type="bibr" rid="CR3">3</xref>].
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Strengths and weaknesses of each score</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"><bold>Strengths</bold></th><th align="left"><bold>Weaknesses</bold></th></tr></thead><tbody><tr><td align="left">Child&#x02013;Pugh score</td><td align="left"><p>Easy to use and interpret</p><p>Well established in clinical practice</p><p>Involves independent predictors of survival in advanced chronic liver disease</p></td><td align="left"><p>Empirical selection of variables</p><p>Arbitrary selection of cut-off values for categorical groups</p><p>Subjective elements</p><p>Inherent malleability of variables with therapeutic intervention</p></td></tr><tr><td align="left">MELD score and variants</td><td align="left"><p>Multivariate analysis used for selection of statistically significant prognostic variables</p><p>&#x02022; Variable significance weighted based on regression coefficient</p><p>Independent of aetiology and sequalae of decompensation (ascites, hepatic encephalopathy, acute variceal bleeding)</p></td><td align="left"><p>Continuous scale is harder to interpret</p><p>Performs worse in specific sub-populations (patients with MAFLD, alcoholic cirrhosis)</p><p>Patient selection in derivation study favoured more healthy individuals</p><p>Inherent malleability of variables with therapeutic intervention</p></td></tr><tr><td align="left">UKELD score</td><td align="left"><p>Targeted score&#x02014;developed specifically in cohort of liver transplant patients</p><p>Multivariate analysis used for selection of statistically significant prognostic variables</p><p>Prospective external validation in derivation study</p></td><td align="left"><p>Only accounts for liver transplantation waitlist survival</p><p>Post-transplant survival not captured prognostically by score</p><p>Hard to interpret and does not provide much valuable information</p><p>Does not account for patients with HCC</p><p>Inherent malleability of variables with therapeutic intervention</p></td></tr><tr><td align="left">CLIF-C ACLF score</td><td align="left"><p>Targeted score&#x02014;developed in cohort of patients experiencing ACLF</p><p>Accounts for independent risks factors derived through statistical analysis</p><p>Distinct survival outcomes obtained</p></td><td align="left"><p>No statistical analysis was conducted to identify markers of organ failure in the context of ACLF&#x02014;was based on pre-existing organ failure models (SOFA)</p><p>Subjective elements</p><p>Only verified in acute setting&#x02014;no evidence on chronic outcomes</p><p>ACLF as a syndrome is still poorly defined</p><p>Inherent malleability of variables with therapeutic intervention</p></td></tr><tr><td align="left">CLIF-C AD score</td><td align="left"><p>Targeted score&#x02014;first to exclude patients with distinct syndrome of ACLF</p><p>Multivariate analysis used for selection of statistically significant prognostic variables</p><p>Sub-distribution to account for patients who undergo liver transplantation</p><p>Distinct survival outcomes derived</p><p>Completely objective score</p></td><td align="left"><p>&#x02022; Does not account for dialysis patients unlike other scores (MELD, MELD-Na)</p><p>Large proportion of patients not accounted for by thresholds set for high and low risk groups</p><p>&#x02022; Selection of cut-offs not statistically based</p><p>Not validated in cohorts containing combination of AD and ACLF patients</p><p>&#x02022; On initial presentation these can be difficult to distinguish</p><p>Inherent malleability of variables with therapeutic intervention</p></td></tr><tr><td align="left">ALBI score</td><td align="left"><p>Targeted score&#x02014;developed specifically for advanced stage HCC patients</p><p>Simple and objective score</p><p>Distinct survival outcomes derived</p></td><td align="left"><p>Potentially may be overly simplistic&#x02014;does not account for many known predictors of mortality</p><p>Developed in cohort of patients with advanced HCC treated with sorafenib</p><p>&#x02022; Excludes intermediate/early-stage HCC and those undergoing more recent novel treatment regimens</p><p>Inherent malleability of variables with therapeutic intervention</p></td></tr><tr><td align="left">FIPS score</td><td align="left"><p>Targeted score&#x02014;developed specifically for patients considered for TIPS insertion</p><p>Multivariable analysis used for selection of statistically significant prognostic variables</p><p>Completely objective score</p></td><td align="left"><p>Does not account for patients with HCC</p><p>Derivation cohort primarily consisted of patients with alcohol associated cirrhosis</p><p>&#x02022; May be less predictive for those with more metabolic risk factors</p><p>No control group in derivation study</p><p>Inherent malleability of variables with therapeutic intervention</p></td></tr></tbody></table></table-wrap></p><p id="Par64">Other weaknesses to consider include the empirical selection of variables and subjectivity of measurement in scores such as the CPS and CLIF-C ACLF. Being continuous scores in nature, the MELD and MELD-Na scores can be difficult to communicate survival outcomes to patients. Furthermore, the UKELD score is hard to interpret and does not account for post-transplant survival [<xref ref-type="bibr" rid="CR74">74</xref>]. The CLIF-C AD score fails to account for a large proportion of patients, assigning them to an arbitrary intermediate risk group. Finally, there is still ambiguity in the definitions associated with ACLF. For further discussion regarding the weaknesses of scores, including the issues with designs of derivation cohorts and real-world interactions between variables, see the Additional File 1.</p><p id="Par65">Table <xref rid="Tab3" ref-type="table">3</xref> summarises some key areas of research whilst acknowledging ongoing studies we have discussed in this narrative review. There are many factors known to be predictive of mortality that are not yet incorporated into predictive scores. There is also limited external validation of novel scores such as the MELD 3.0 and CLIF-C AD scores. In the setting of liver transplantation, it would be beneficial to establish if gender disparities are addressed by the MELD 3.0 with prospective cohorts and meta-analyses. Unifying the definitions of ACLF is important in ensuring the CLIF-C ACLF score can be used optimally in clinical practice. Prospective trials validating predictive factors are currently being undertaken. Finally, as our understanding of the complexities of metabolic dysfunction associated with liver disease increases, identification of previously excluded patients with disease is occurring [<xref ref-type="bibr" rid="CR7">7</xref>]. Scores developed specifically for this disease are needed to account for a larger, heterogeneous group of patients.
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Suggestions for future research with current areas of ongoing research</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Future areas for research</th></tr></thead><tbody><tr><td align="left">Addressing the absence of known predictive factors in currently used score</td></tr><tr><td align="left"><italic>Sarcopenia, myosteatosis and gender are all predictive factors that are under accounted for</italic></td></tr><tr><td align="left"><italic>A Cochrane protocol for a meta-analysis evaluating the predictive capacity of current scores is available</italic><sup><italic>55</italic></sup></td></tr><tr><td align="left"><italic>Scores developed over recent years such as the MELD 3.0, CLIF-C AD and modified Liaoning scores should be included in updated meta-analyses</italic></td></tr><tr><td align="left">The ongoing under prioritisation of females for liver transplantation</td></tr><tr><td align="left"><italic>Prospective studies evaluating new allocation scores such as the MELD 3.0 and GEMA score are needed</italic></td></tr><tr><td align="left">Novel predictors of outcomes in patients with ACLF</td></tr><tr><td align="left"><italic>The derivation study of the CLIF-C ACLF score recruited a cohort with aetiology largely related to alcohol misuse. It would be of use to determine if different causes of ACLF are as effectively captured</italic></td></tr><tr><td align="left"><italic>There are two current prospective studies registered investigating predictive factors - NCT05393453 and NCT06069284</italic></td></tr><tr><td align="left">Improved predictive models for mortality following TIPS insertion</td></tr><tr><td align="left">There are two meta-analyses currently registered on PROSPERO by Chi et al. (CRD42024528193) and Huang et al. (CRD420251007253) that will provide further prognostic information on each score</td></tr><tr><td align="left">With the novel inclusive diagnostic criteria for metabolic dysfunction associated liver disease increased granularity on outcomes for these patients needs to be sought</td></tr><tr><td align="left"><italic>The BOMASH study (NCT06813508) has been designed to investigate outcomes in patients with MAFLD</italic></td></tr><tr><td align="left">Incorporating the use of machine learning and AI models into predictive algorithms</td></tr></tbody></table></table-wrap></p><p id="Par66">Current prognostic models in advanced liver disease rely on predictive analytics; the use of historical data to model future events. Prescriptive analytics takes predictive analyses and applies them to a continually evolving model to better predict outcomes [<xref ref-type="bibr" rid="CR121">121</xref>]. The use of artificial intelligence through neural networks and machine learning in personalising survival modelling in patients with liver disease is of future interest [<xref ref-type="bibr" rid="CR122">122</xref>]. The use of machine learning based on dynamic changes is highly effective in patients admitted to the intensive care unit [<xref ref-type="bibr" rid="CR123">123</xref>, <xref ref-type="bibr" rid="CR124">124</xref>]. Future studies investigating the use of machine learning and neural networks in predicting mortality and other relevant outcomes are warranted. The evolving heterogeneity of our understanding of liver disease may be best addressed by the personalised medicine AI promises.</p><p id="Par67">Supplementary information.</p><p id="Par68">Additional File 1: Table S1-6. Table S1&#x02014;Mortality rates for CPS Classes. Table S2&#x02014;3-month mortality in patients undergoing liver transplantation by MELD score. Table S3&#x02014;3-month mortality in patients undergoing liver transplant by MELD-Na Score. Table S4&#x02014;1-year mortality without transplantation as per the UKELD Score. Table S5&#x02014;CLIF-OF Score Rubric. Table S6&#x02014;Median survival based on ALBI score.</p></sec><sec id="Sec11" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12916_2025_4185_MOESM1_ESM.docx"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ACLD</term><def><p id="Par4">Advanced chronic liver disease</p></def></def-item><def-item><term>ACLF</term><def><p id="Par5">Acute-on-chronic liver failure</p></def></def-item><def-item><term>AD</term><def><p id="Par6">Acute decompensation</p></def></def-item><def-item><term>ALBI</term><def><p id="Par7">Albumin-bilirubin score</p></def></def-item><def-item><term>APASL</term><def><p id="Par8">Asian Pacific Association for Study of the Liver</p></def></def-item><def-item><term>AUROC</term><def><p id="Par9">Area under the receiver operating characteristic curve</p></def></def-item><def-item><term>BCLC</term><def><p id="Par10">Barcelona Clinic Liver Cancer</p></def></def-item><def-item><term>CLIF-C</term><def><p id="Par11">Chronic Liver Failure Consortium</p></def></def-item><def-item><term>CPS</term><def><p id="Par12">Child-Pugh score</p></def></def-item><def-item><term>ePTFE-SG</term><def><p id="Par13">Expanding PolyTetraFluoroEthylene-covered tent Graft</p></def></def-item><def-item><term>FIPS</term><def><p id="Par14">Frieberg Index of Post-TIPS Survival</p></def></def-item><def-item><term>GEMA</term><def><p id="Par15">Gender Equity Model for Liver Allocation</p></def></def-item><def-item><term>GI</term><def><p id="Par16">Gastrointestinal</p></def></def-item><def-item><term>HBV</term><def><p id="Par17">Hepatitis B virus</p></def></def-item><def-item><term>HCC</term><def><p id="Par18">Hepatocellular carcinoma</p></def></def-item><def-item><term>HCV</term><def><p id="Par19">Hepatitis C virus</p></def></def-item><def-item><term>INR</term><def><p id="Par20">International normalised ratio</p></def></def-item><def-item><term>MAFLD</term><def><p id="Par21">Metabolic dysfunction-associated fatty liver disease</p></def></def-item><def-item><term>MELD</term><def><p id="Par22">Model for End-Stage Liver Disease</p></def></def-item><def-item><term>OLT</term><def><p id="Par23">Orthotopic liver transplant</p></def></def-item><def-item><term>SOFA</term><def><p id="Par24">Sepsis Organ Failure Assessment</p></def></def-item><def-item><term>TACE</term><def><p id="Par25">Transarterial chemoembolisation</p></def></def-item><def-item><term>TIPS</term><def><p id="Par26">Transjugular intrahepatic portosystemic shunt</p></def></def-item><def-item><term>TNM</term><def><p id="Par27">Tumour lymph node metastasis</p></def></def-item><def-item><term>UK</term><def><p id="Par28">United Kingdom</p></def></def-item><def-item><term>UKELD</term><def><p id="Par29">United Kingdom End-Stage Liver Disease</p></def></def-item><def-item><term>WCC</term><def><p id="Par30">White cell count</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>N/A.</p></ack><notes notes-type="author-contribution"><title>Authors'contribution
</title><p>OM, WM and GA review conception; OM first draft composition; WM, SR, JG, GA substantial revisions and editing; all authors final review.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by the Ainsworth bequest to Western Sydney University.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials
</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par69">N/A.</p></notes><notes id="FPar3"><title>Consent for publication</title><p id="Par70">N/A.</p></notes><notes id="FPar4" notes-type="COI-statement"><title>Competing interests
</title><p id="Par71">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References
</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Child</surname><given-names>CG</given-names></name><name><surname>Turcotte</surname><given-names>JG</given-names></name></person-group><article-title>Surgery and portal hypertension</article-title><source>Major Probl Clin Surg</source><year>1964</year><volume>1</volume><fpage>1</fpage><lpage>85</lpage><?supplied-pmid 4950264?><pub-id pub-id-type="pmid">4950264</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg. 1964;1:1&#x02013;85.<pub-id pub-id-type="pmid">4950264</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>D'Amico</surname><given-names>G</given-names></name><name><surname>Garcia-Tsao</surname><given-names>G</given-names></name><name><surname>Pagliaro</surname><given-names>L</given-names></name></person-group><article-title>Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies</article-title><source>J Hepatol</source><year>2006</year><volume>44</volume><issue>1</issue><fpage>217</fpage><lpage>231</lpage><?supplied-pmid 16298014?><pub-id pub-id-type="pmid">16298014</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">D&#x02019;Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217&#x02013;31.<pub-id pub-id-type="pmid">16298014</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Durand</surname><given-names>F</given-names></name><name><surname>Valla</surname><given-names>D</given-names></name></person-group><article-title>Assessment of the prognosis of cirrhosis: child-Pugh versus MELD</article-title><source>J Hepatol</source><year>2005</year><volume>42</volume><issue>1</issue><fpage>S100</fpage><lpage>S107</lpage><?supplied-pmid 15777564?><pub-id pub-id-type="pmid">15777564</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Durand F, Valla D. Assessment of the prognosis of cirrhosis: child-Pugh versus MELD. J Hepatol. 2005;42(1):S100&#x02013;7.<pub-id pub-id-type="pmid">15777564</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Valery</surname><given-names>PC</given-names></name><name><surname>McPhail</surname><given-names>S</given-names></name><name><surname>Stuart</surname><given-names>KA</given-names></name><name><surname>Hartel</surname><given-names>G</given-names></name><name><surname>Clark</surname><given-names>PJ</given-names></name><name><surname>O'Beirne</surname><given-names>J</given-names></name><etal/></person-group><article-title>Changing prevalence of aetiological factors and comorbidities among Australians hospitalised for cirrhosis</article-title><source>Intern Med J</source><year>2021</year><volume>51</volume><issue>5</issue><fpage>691</fpage><lpage>698</lpage><?supplied-pmid 32096890?><pub-id pub-id-type="pmid">32096890</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Valery PC, McPhail S, Stuart KA, Hartel G, Clark PJ, O&#x02019;Beirne J, et al. Changing prevalence of aetiological factors and comorbidities among Australians hospitalised for cirrhosis. Intern Med J. 2021;51(5):691&#x02013;8.<pub-id pub-id-type="pmid">32096890</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">Gu W, Hortlik H, Erasmus H-P, Schaaf L, Zeleke Y, Uschner FE, et al. Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018). The Lancet Regional Health - Europe. 2022;12.</mixed-citation></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Cheemerla</surname><given-names>S</given-names></name><name><surname>Balakrishnan</surname><given-names>M</given-names></name></person-group><article-title>Global Epidemiology of Chronic Liver Disease</article-title><source>Clin Liver Dis</source><year>2021</year><volume>17</volume><issue>5</issue><fpage>365</fpage><lpage>370</lpage></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Cheemerla S, Balakrishnan M. Global Epidemiology of Chronic Liver Disease. Clin Liver Dis. 2021;17(5):365&#x02013;70.</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>W-K</given-names></name><name><surname>George</surname><given-names>J</given-names></name></person-group><article-title>Metabolic fatty liver syndromes: where do we stand in 2024?</article-title><source>J Gastroenterol Hepatol</source><year>2024</year><volume>39</volume><issue>4</issue><fpage>613</fpage><lpage>614</lpage><?supplied-pmid 38357837?><pub-id pub-id-type="pmid">38357837</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Chan W-K, George J. Metabolic fatty liver syndromes: where do we stand in 2024? J Gastroenterol Hepatol. 2024;39(4):613&#x02013;4.<pub-id pub-id-type="pmid">38357837</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Trebicka</surname><given-names>J</given-names></name><name><surname>Fernandez</surname><given-names>J</given-names></name><name><surname>Papp</surname><given-names>M</given-names></name><name><surname>Caraceni</surname><given-names>P</given-names></name><name><surname>Laleman</surname><given-names>W</given-names></name><name><surname>Gambino</surname><given-names>C</given-names></name><etal/></person-group><article-title>The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology</article-title><source>J Hepatol</source><year>2020</year><volume>73</volume><issue>4</issue><fpage>842</fpage><lpage>854</lpage><?supplied-pmid 32673741?><pub-id pub-id-type="pmid">32673741</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Trebicka J, Fernandez J, Papp M, Caraceni P, Laleman W, Gambino C, et al. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. J Hepatol. 2020;73(4):842&#x02013;54.<pub-id pub-id-type="pmid">32673741</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Jalan</surname><given-names>R</given-names></name><name><surname>Gines</surname><given-names>P</given-names></name><name><surname>Olson</surname><given-names>JC</given-names></name><name><surname>Mookerjee</surname><given-names>RP</given-names></name><name><surname>Moreau</surname><given-names>R</given-names></name><name><surname>Garcia-Tsao</surname><given-names>G</given-names></name><etal/></person-group><article-title>Acute-on chronic liver failure</article-title><source>J Hepatol</source><year>2012</year><volume>57</volume><issue>6</issue><fpage>1336</fpage><lpage>1348</lpage><?supplied-pmid 22750750?><pub-id pub-id-type="pmid">22750750</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Jalan R, Gines P, Olson JC, Mookerjee RP, Moreau R, Garcia-Tsao G, et al. Acute-on chronic liver failure. J Hepatol. 2012;57(6):1336&#x02013;48.<pub-id pub-id-type="pmid">22750750</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Merli</surname><given-names>M</given-names></name><name><surname>Riggio</surname><given-names>O</given-names></name><name><surname>Dally</surname><given-names>L</given-names></name></person-group><article-title>Does malnutrition affect survival in cirrhosis?</article-title><source>Hepatology</source><year>1996</year><volume>23</volume><issue>5</issue><fpage>1041</fpage><lpage>1046</lpage><?supplied-pmid 8621131?><pub-id pub-id-type="pmid">8621131</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Merli M, Riggio O, Dally L. Does malnutrition affect survival in cirrhosis? Hepatology. 1996;23(5):1041&#x02013;6.<pub-id pub-id-type="pmid">8621131</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Pugh</surname><given-names>RN</given-names></name><name><surname>Murray-Lyon</surname><given-names>IM</given-names></name><name><surname>Dawson</surname><given-names>JL</given-names></name><name><surname>Pietroni</surname><given-names>MC</given-names></name><name><surname>Williams</surname><given-names>R</given-names></name></person-group><article-title>Transection of the oesophagus for bleeding oesophageal varices</article-title><source>Br J Surg</source><year>1973</year><volume>60</volume><issue>8</issue><fpage>646</fpage><lpage>649</lpage><?supplied-pmid 4541913?><pub-id pub-id-type="pmid">4541913</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646&#x02013;9.<pub-id pub-id-type="pmid">4541913</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Schizas</surname><given-names>D</given-names></name><name><surname>Giannopoulos</surname><given-names>S</given-names></name><name><surname>Vailas</surname><given-names>M</given-names></name><name><surname>Mylonas</surname><given-names>KS</given-names></name><name><surname>Giannopoulos</surname><given-names>S</given-names></name><name><surname>Moris</surname><given-names>D</given-names></name><etal/></person-group><article-title>The impact of cirrhosis on esophageal cancer surgery: An up-to-date meta-analysis</article-title><source>Am J Surg</source><year>2020</year><volume>220</volume><issue>4</issue><fpage>865</fpage><lpage>872</lpage><?supplied-pmid 32107011?><pub-id pub-id-type="pmid">32107011</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Schizas D, Giannopoulos S, Vailas M, Mylonas KS, Giannopoulos S, Moris D, et al. The impact of cirrhosis on esophageal cancer surgery: An up-to-date meta-analysis. Am J Surg. 2020;220(4):865&#x02013;72.<pub-id pub-id-type="pmid">32107011</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Schizas</surname><given-names>D</given-names></name><name><surname>Peppas</surname><given-names>S</given-names></name><name><surname>Giannopoulos</surname><given-names>S</given-names></name><name><surname>Lagopoulou</surname><given-names>V</given-names></name><name><surname>Mylonas</surname><given-names>KS</given-names></name><name><surname>Giannopoulos</surname><given-names>S</given-names></name><etal/></person-group><article-title>The Impact of Cirrhosis on Pancreatic Cancer Surgery: A Systematic Review and Meta-Analysis</article-title><source>World J Surg</source><year>2021</year><volume>45</volume><issue>2</issue><fpage>562</fpage><lpage>570</lpage><?supplied-pmid 33073316?><pub-id pub-id-type="pmid">33073316</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Schizas D, Peppas S, Giannopoulos S, Lagopoulou V, Mylonas KS, Giannopoulos S, et al. The Impact of Cirrhosis on Pancreatic Cancer Surgery: A Systematic Review and Meta-Analysis. World J Surg. 2021;45(2):562&#x02013;70.<pub-id pub-id-type="pmid">33073316</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Northup</surname><given-names>PG</given-names></name><name><surname>Friedman</surname><given-names>LS</given-names></name><name><surname>Kamath</surname><given-names>PS</given-names></name></person-group><article-title>AGA Clinical Practice Update on Surgical Risk Assessment and Perioperative Management in Cirrhosis: Expert Review</article-title><source>Clin Gastroenterol Hepatol</source><year>2019</year><volume>17</volume><issue>4</issue><fpage>595</fpage><lpage>606</lpage><?supplied-pmid 30273751?><pub-id pub-id-type="pmid">30273751</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Northup PG, Friedman LS, Kamath PS. AGA Clinical Practice Update on Surgical Risk Assessment and Perioperative Management in Cirrhosis: Expert Review. Clin Gastroenterol Hepatol. 2019;17(4):595&#x02013;606.<pub-id pub-id-type="pmid">30273751</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Reig</surname><given-names>M</given-names></name><name><surname>Forner</surname><given-names>A</given-names></name><name><surname>Rimola</surname><given-names>J</given-names></name><name><surname>Ferrer-F&#x000e0;brega</surname><given-names>J</given-names></name><name><surname>Burrel</surname><given-names>M</given-names></name><name><surname>Garcia-Criado</surname><given-names>&#x000c1;</given-names></name><etal/></person-group><article-title>BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update</article-title><source>J Hepatol</source><year>2022</year><volume>76</volume><issue>3</issue><fpage>681</fpage><lpage>693</lpage><?supplied-pmid 34801630?><pub-id pub-id-type="pmid">34801630</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Reig M, Forner A, Rimola J, Ferrer-F&#x000e0;brega J, Burrel M, Garcia-Criado &#x000c1;, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681&#x02013;93.<pub-id pub-id-type="pmid">34801630</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Delis</surname><given-names>SG</given-names></name><name><surname>Dervenis</surname><given-names>C</given-names></name></person-group><article-title>Selection criteria for liver resection in patients with hepatocellular carcinoma and chronic liver disease</article-title><source>World J Gastroenterol</source><year>2008</year><volume>14</volume><issue>22</issue><fpage>3452</fpage><lpage>3460</lpage><?supplied-pmid 18567070?><pub-id pub-id-type="pmid">18567070</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Delis SG, Dervenis C. Selection criteria for liver resection in patients with hepatocellular carcinoma and chronic liver disease. World J Gastroenterol. 2008;14(22):3452&#x02013;60.<pub-id pub-id-type="pmid">18567070</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Gordan</surname><given-names>JD</given-names></name><name><surname>Kennedy</surname><given-names>EB</given-names></name><name><surname>Abou-Alfa</surname><given-names>GK</given-names></name><name><surname>Beg</surname><given-names>MS</given-names></name><name><surname>Brower</surname><given-names>ST</given-names></name><name><surname>Gade</surname><given-names>TP</given-names></name><etal/></person-group><article-title>Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline</article-title><source>J Clin Oncol</source><year>2020</year><volume>38</volume><issue>36</issue><fpage>4317</fpage><lpage>4345</lpage><?supplied-pmid 33197225?><pub-id pub-id-type="pmid">33197225</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Gordan JD, Kennedy EB, Abou-Alfa GK, Beg MS, Brower ST, Gade TP, et al. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. J Clin Oncol. 2020;38(36):4317&#x02013;45.<pub-id pub-id-type="pmid">33197225</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Greten</surname><given-names>TF</given-names></name><name><surname>Abou-Alfa</surname><given-names>GK</given-names></name><name><surname>Cheng</surname><given-names>AL</given-names></name><name><surname>Duffy</surname><given-names>AG</given-names></name><name><surname>El-Khoueiry</surname><given-names>AB</given-names></name><name><surname>Finn</surname><given-names>RS</given-names></name><etal/></person-group><article-title>Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma</article-title><source>J Immunother Cancer</source><year>2021</year><volume>9</volume><issue>9</issue><fpage>256</fpage></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Greten TF, Abou-Alfa GK, Cheng AL, Duffy AG, El-Khoueiry AB, Finn RS, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. J Immunother Cancer. 2021;9(9):256.</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Tampaki M, Papatheodoridis GV, Cholongitas E. Management of Hepatocellular Carcinoma in Decompensated Cirrhotic Patients: A Comprehensive Overview. Cancers. 2023;15(4).</mixed-citation></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Salpeter</surname><given-names>SR</given-names></name><name><surname>Luo</surname><given-names>EJ</given-names></name><name><surname>Malter</surname><given-names>DS</given-names></name><name><surname>Stuart</surname><given-names>B</given-names></name></person-group><article-title>Systematic review of noncancer presentations with a median survival of 6 months or less</article-title><source>Am J Med</source><year>2012</year><volume>125</volume><issue>5</issue><fpage>512.e1</fpage><lpage>.e16</lpage><?supplied-pmid 22030293?><pub-id pub-id-type="pmid">22030293</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Salpeter SR, Luo EJ, Malter DS, Stuart B. Systematic review of noncancer presentations with a median survival of 6 months or less. Am J Med. 2012;125(5):512.e1-.e16.<pub-id pub-id-type="pmid">22030293</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Botta</surname><given-names>F</given-names></name></person-group><article-title>MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study</article-title><source>Gut</source><year>2003</year><volume>52</volume><issue>1</issue><fpage>134</fpage><lpage>139</lpage><?supplied-pmid 12477775?><pub-id pub-id-type="pmid">12477775</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Botta F. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut. 2003;52(1):134&#x02013;9.<pub-id pub-id-type="pmid">12477775</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>S-Z</given-names></name><name><surname>Nie</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name></person-group><article-title>Assessing the Prognostic Performance of the Child-Pugh, Model for End-Stage Liver Disease, and Albumin-Bilirubin Scores in Patients with Decompensated Cirrhosis: A Large Asian Cohort from Gastroenterology Department</article-title><source>Dis Markers</source><year>2020</year><volume>2020</volume><fpage>1</fpage><lpage>9</lpage></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Wan S-Z, Nie Y, Zhang Y, Liu C, Zhu X. Assessing the Prognostic Performance of the Child-Pugh, Model for End-Stage Liver Disease, and Albumin-Bilirubin Scores in Patients with Decompensated Cirrhosis: A Large Asian Cohort from Gastroenterology Department. Dis Markers. 2020;2020:1&#x02013;9.</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Fern&#x000e1;ndez-Esparrach</surname><given-names>G</given-names></name><name><surname>S&#x000e1;nchez-Fueyo</surname><given-names>A</given-names></name><name><surname>Gin&#x000e8;s</surname><given-names>P</given-names></name><name><surname>Uriz</surname><given-names>J</given-names></name><name><surname>Quint&#x000f3;</surname><given-names>L</given-names></name><name><surname>Ventura</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>A prognostic model for predicting survival in cirrhosis with ascites</article-title><source>J Hepatol</source><year>2001</year><volume>34</volume><issue>1</issue><fpage>46</fpage><lpage>52</lpage><?supplied-pmid 11211907?><pub-id pub-id-type="pmid">11211907</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Fern&#x000e1;ndez-Esparrach G, S&#x000e1;nchez-Fueyo A, Gin&#x000e8;s P, Uriz J, Quint&#x000f3; L, Ventura PJ, et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol. 2001;34(1):46&#x02013;52.<pub-id pub-id-type="pmid">11211907</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>SL</given-names></name><name><surname>Zheng</surname><given-names>YX</given-names></name><name><surname>Tian</surname><given-names>ZW</given-names></name><name><surname>Chen</surname><given-names>MS</given-names></name><name><surname>Tan</surname><given-names>HZ</given-names></name></person-group><article-title>Scoring systems for prediction of mortality in decompensated liver cirrhosis: A meta-analysis of test accuracy</article-title><source>World J Clin Cases</source><year>2018</year><volume>6</volume><issue>15</issue><fpage>995</fpage><lpage>1006</lpage><?supplied-pmid 30568954?><pub-id pub-id-type="pmid">30568954</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Wu SL, Zheng YX, Tian ZW, Chen MS, Tan HZ. Scoring systems for prediction of mortality in decompensated liver cirrhosis: A meta-analysis of test accuracy. World J Clin Cases. 2018;6(15):995&#x02013;1006.<pub-id pub-id-type="pmid">30568954</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Peng Y, Qi X, Guo X. Child-Pugh Versus MELD Score for the Assessment of Prognosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis of Observational Studies. Medicine (Baltimore). 2016;95(8).</mixed-citation></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Barosa</surname><given-names>R</given-names></name><name><surname>Roque Ramos</surname><given-names>L</given-names></name><name><surname>Patita</surname><given-names>M</given-names></name><name><surname>Nunes</surname><given-names>G</given-names></name><name><surname>Fonseca</surname><given-names>J</given-names></name></person-group><article-title>CLIF-C ACLF score is a better mortality predictor than MELD, MELD-Na and CTP in patients with Acute on Chronic Liver Failure admitted to the ward</article-title><source>Revista Espa&#x000f1;ola de Enfermedades Digestivas.</source><year>2017</year><volume>109</volume><fpage>109</fpage></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Barosa R, Roque Ramos L, Patita M, Nunes G, Fonseca J. CLIF-C ACLF score is a better mortality predictor than MELD, MELD-Na and CTP in patients with Acute on Chronic Liver Failure admitted to the ward. Revista Espa&#x000f1;ola de Enfermedades Digestivas. 2017;109:109.</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Ramzan M, Iqbal A, Murtaza HG, Javed N, Rasheed G, Bano K. Comparison of CLIF-C ACLF Score and MELD Score in Predicting ICU Mortality in Patients with Acute-On-Chronic Liver Failure. Cureus. 2020;12(2).</mixed-citation></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>YX</given-names></name><name><surname>Zhong</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>YJ</given-names></name><name><surname>Fan</surname><given-names>XG</given-names></name></person-group><article-title>Performance of scoring systems to predict mortality of patients with acute-on-chronic liver failure: A systematic review and meta-analysis</article-title><source>J Gastroenterol Hepatol</source><year>2017</year><volume>32</volume><issue>10</issue><fpage>1668</fpage><lpage>1678</lpage><?supplied-pmid 28303605?><pub-id pub-id-type="pmid">28303605</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Zheng YX, Zhong X, Li YJ, Fan XG. Performance of scoring systems to predict mortality of patients with acute-on-chronic liver failure: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2017;32(10):1668&#x02013;78.<pub-id pub-id-type="pmid">28303605</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Pohl</surname><given-names>J</given-names></name><name><surname>Gebauer</surname><given-names>B</given-names></name><name><surname>Gebert</surname><given-names>P</given-names></name><name><surname>Tacke</surname><given-names>F</given-names></name><name><surname>Wree</surname><given-names>A</given-names></name></person-group><article-title>Predicting survival after TIPS: Child Pugh score is not inferior to MELD and FIPS score &#x02013; back to basics?</article-title><source>J Hepatol</source><year>2021</year><volume>75</volume><issue>6</issue><fpage>1505</fpage><lpage>1506</lpage><?supplied-pmid 34265365?><pub-id pub-id-type="pmid">34265365</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Pohl J, Gebauer B, Gebert P, Tacke F, Wree A. Predicting survival after TIPS: Child Pugh score is not inferior to MELD and FIPS score &#x02013; back to basics? J Hepatol. 2021;75(6):1505&#x02013;6.<pub-id pub-id-type="pmid">34265365</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name></person-group><article-title>Predictive Accuracy Comparison of Prognostic Scoring Systems for Survival in Patients Undergoing TIPS Placement: A Systematic Review and Meta-analysis</article-title><source>Acad Radiol</source><year>2024</year><volume>31</volume><issue>9</issue><fpage>3688</fpage><lpage>3710</lpage><?supplied-pmid 38000922?><pub-id pub-id-type="pmid">38000922</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Zhao Y, Wang Y, Xu J. Predictive Accuracy Comparison of Prognostic Scoring Systems for Survival in Patients Undergoing TIPS Placement: A Systematic Review and Meta-analysis. Acad Radiol. 2024;31(9):3688&#x02013;710.<pub-id pub-id-type="pmid">38000922</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Gananandan</surname><given-names>K</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Mehta</surname><given-names>G</given-names></name></person-group><article-title>Systematic review and meta-analysis of biomarkers predicting decompensation in patients with compensated cirrhosis</article-title><source>BMJ Open Gastroenterol</source><year>2024</year><volume>11</volume><issue>1</issue><fpage>e001430</fpage><?supplied-pmid 39182920?><pub-id pub-id-type="pmid">39182920</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Gananandan K, Singh R, Mehta G. Systematic review and meta-analysis of biomarkers predicting decompensation in patients with compensated cirrhosis. BMJ Open Gastroenterol. 2024;11(1):e001430.<pub-id pub-id-type="pmid">39182920</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Bradburn</surname><given-names>MJ</given-names></name><name><surname>Clark</surname><given-names>TG</given-names></name><name><surname>Love</surname><given-names>SB</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>Survival Analysis Part II: Multivariate data analysis &#x02013; an introduction to concepts and methods</article-title><source>Br J Cancer</source><year>2003</year><volume>89</volume><issue>3</issue><fpage>431</fpage><lpage>436</lpage><?supplied-pmid 12888808?><pub-id pub-id-type="pmid">12888808</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Bradburn MJ, Clark TG, Love SB, Altman DG. Survival Analysis Part II: Multivariate data analysis &#x02013; an introduction to concepts and methods. Br J Cancer. 2003;89(3):431&#x02013;6.<pub-id pub-id-type="pmid">12888808</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Charif</surname><given-names>I</given-names></name><name><surname>Saada</surname><given-names>K</given-names></name><name><surname>Ihsane</surname><given-names>M</given-names></name><name><surname>Yousfi</surname><given-names>M</given-names></name><name><surname>Benajah</surname><given-names>D</given-names></name><name><surname>Abkari</surname><given-names>M</given-names></name><etal/></person-group><article-title>Predictors of Intra-Hospital Mortality in Patients with Cirrhosis</article-title><source>Open J Gastroenterol</source><year>2014</year><volume>04</volume><fpage>141</fpage><lpage>148</lpage></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Charif I, Saada K, Ihsane M, Yousfi M, Benajah D, Abkari M, et al. Predictors of Intra-Hospital Mortality in Patients with Cirrhosis. Open J Gastroenterol. 2014;04:141&#x02013;8.</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Nair</surname><given-names>S</given-names></name><name><surname>Verma</surname><given-names>S</given-names></name><name><surname>Thuluvath</surname><given-names>PJ</given-names></name></person-group><article-title>Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation</article-title><source>Hepatology</source><year>2002</year><volume>35</volume><issue>5</issue><fpage>1179</fpage><lpage>1185</lpage><?supplied-pmid 11981768?><pub-id pub-id-type="pmid">11981768</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Nair S, Verma S, Thuluvath PJ. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology. 2002;35(5):1179&#x02013;85.<pub-id pub-id-type="pmid">11981768</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>RA</given-names></name><name><surname>Austin</surname><given-names>AS</given-names></name><name><surname>Kolhe</surname><given-names>NV</given-names></name><name><surname>McIntyre</surname><given-names>CW</given-names></name><name><surname>Selby</surname><given-names>NM</given-names></name></person-group><article-title>Acute kidney injury is independently associated with death in patients with cirrhosis</article-title><source>Frontline Gastroenterol</source><year>2013</year><volume>4</volume><issue>3</issue><fpage>191</fpage><lpage>197</lpage><?supplied-pmid 24660054?><pub-id pub-id-type="pmid">24660054</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Scott RA, Austin AS, Kolhe NV, McIntyre CW, Selby NM. Acute kidney injury is independently associated with death in patients with cirrhosis. Frontline Gastroenterol. 2013;4(3):191&#x02013;7.<pub-id pub-id-type="pmid">24660054</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Angeli</surname><given-names>P</given-names></name><name><surname>Wong</surname><given-names>F</given-names></name><name><surname>Watson</surname><given-names>H</given-names></name><name><surname>Gin&#x000e8;s</surname><given-names>P</given-names></name></person-group><article-title>Hyponatremia in cirrhosis: Results of a patient population survey</article-title><source>Hepatology</source><year>2006</year><volume>44</volume><issue>6</issue><fpage>1535</fpage><lpage>1542</lpage><?supplied-pmid 17133458?><pub-id pub-id-type="pmid">17133458</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Angeli P, Wong F, Watson H, Gin&#x000e8;s P. Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology. 2006;44(6):1535&#x02013;42.<pub-id pub-id-type="pmid">17133458</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>WR</given-names></name><name><surname>Biggins</surname><given-names>SW</given-names></name><name><surname>Kremers</surname><given-names>WK</given-names></name><name><surname>Wiesner</surname><given-names>RH</given-names></name><name><surname>Kamath</surname><given-names>PS</given-names></name><name><surname>Benson</surname><given-names>JT</given-names></name><etal/></person-group><article-title>Hyponatremia and Mortality among Patients on the Liver-Transplant Waiting List</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><issue>10</issue><fpage>1018</fpage><lpage>1026</lpage><?supplied-pmid 18768945?><pub-id pub-id-type="pmid">18768945</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al. Hyponatremia and Mortality among Patients on the Liver-Transplant Waiting List. N Engl J Med. 2008;359(10):1018&#x02013;26.<pub-id pub-id-type="pmid">18768945</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>John</surname><given-names>S</given-names></name><name><surname>Thuluvath</surname><given-names>PJ</given-names></name></person-group><article-title>Hyponatremia in cirrhosis: pathophysiology and management</article-title><source>World J Gastroenterol</source><year>2015</year><volume>21</volume><issue>11</issue><fpage>3197</fpage><lpage>3205</lpage><?supplied-pmid 25805925?><pub-id pub-id-type="pmid">25805925</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">John S, Thuluvath PJ. Hyponatremia in cirrhosis: pathophysiology and management. World J Gastroenterol. 2015;21(11):3197&#x02013;205.<pub-id pub-id-type="pmid">25805925</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>F</given-names></name></person-group><article-title>Recent advances in our understanding of hepatorenal syndrome</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2012</year><volume>9</volume><issue>7</issue><fpage>382</fpage><lpage>391</lpage><?supplied-pmid 22614754?><pub-id pub-id-type="pmid">22614754</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Wong F. Recent advances in our understanding of hepatorenal syndrome. Nat Rev Gastroenterol Hepatol. 2012;9(7):382&#x02013;91.<pub-id pub-id-type="pmid">22614754</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Royston</surname><given-names>P</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Sauerbrei</surname><given-names>W</given-names></name></person-group><article-title>Dichotomizing continuous predictors in multiple regression: a bad idea</article-title><source>Stat Med</source><year>2006</year><volume>25</volume><issue>1</issue><fpage>127</fpage><lpage>141</lpage><?supplied-pmid 16217841?><pub-id pub-id-type="pmid">16217841</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med. 2006;25(1):127&#x02013;41.<pub-id pub-id-type="pmid">16217841</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Malinchoc</surname><given-names>M</given-names></name><name><surname>Kamath</surname><given-names>PS</given-names></name><name><surname>Gordon</surname><given-names>FD</given-names></name><name><surname>Peine</surname><given-names>CJ</given-names></name><name><surname>Rank</surname><given-names>J</given-names></name><name><surname>Ter Borg</surname><given-names>PCJ</given-names></name></person-group><article-title>A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts</article-title><source>Hepatology</source><year>2000</year><volume>31</volume><issue>4</issue><fpage>864</fpage><lpage>871</lpage><?supplied-pmid 10733541?><pub-id pub-id-type="pmid">10733541</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, Ter Borg PCJ. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31(4):864&#x02013;71.<pub-id pub-id-type="pmid">10733541</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Wiesner</surname><given-names>R</given-names></name></person-group><article-title>MELD and PELD: Application of survival models to liver allocation</article-title><source>Liver Transpl</source><year>2001</year><volume>7</volume><issue>7</issue><fpage>567</fpage><lpage>580</lpage><?supplied-pmid 11460223?><pub-id pub-id-type="pmid">11460223</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Wiesner R. MELD and PELD: Application of survival models to liver allocation. Liver Transpl. 2001;7(7):567&#x02013;80.<pub-id pub-id-type="pmid">11460223</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Wiesner</surname><given-names>R</given-names></name><name><surname>Edwards</surname><given-names>E</given-names></name><name><surname>Freeman</surname><given-names>R</given-names></name><name><surname>Harper</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>R</given-names></name><name><surname>Kamath</surname><given-names>P</given-names></name><etal/></person-group><article-title>Model for end-stage liver disease (MELD) and allocation of donor livers</article-title><source>Gastroenterology</source><year>2003</year><volume>124</volume><issue>1</issue><fpage>91</fpage><lpage>96</lpage><?supplied-pmid 12512033?><pub-id pub-id-type="pmid">12512033</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124(1):91&#x02013;6.<pub-id pub-id-type="pmid">12512033</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Gin&#x000e8;s</surname><given-names>P</given-names></name><name><surname>Guevara</surname><given-names>M</given-names></name></person-group><article-title>Hyponatremia in cirrhosis: Pathogenesis, clinical significance, and management</article-title><source>Hepatology</source><year>2008</year><volume>48</volume><issue>3</issue><fpage>1002</fpage><lpage>1010</lpage><?supplied-pmid 18671303?><pub-id pub-id-type="pmid">18671303</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Gin&#x000e8;s P, Guevara M. Hyponatremia in cirrhosis: Pathogenesis, clinical significance, and management. Hepatology. 2008;48(3):1002&#x02013;10.<pub-id pub-id-type="pmid">18671303</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Londo&#x000f1;o</surname><given-names>MC</given-names></name><name><surname>Guevara</surname><given-names>M</given-names></name><name><surname>Rimola</surname><given-names>A</given-names></name><name><surname>Navasa</surname><given-names>M</given-names></name><name><surname>Taur&#x000e0;</surname><given-names>P</given-names></name><name><surname>Mas</surname><given-names>A</given-names></name><etal/></person-group><article-title>Hyponatremia Impairs Early Posttransplantation Outcome in Patients With Cirrhosis Undergoing Liver Transplantation</article-title><source>Gastroenterology</source><year>2006</year><volume>130</volume><issue>4</issue><fpage>1135</fpage><lpage>1143</lpage><?supplied-pmid 16618408?><pub-id pub-id-type="pmid">16618408</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Londo&#x000f1;o MC, Guevara M, Rimola A, Navasa M, Taur&#x000e0; P, Mas A, et al. Hyponatremia Impairs Early Posttransplantation Outcome in Patients With Cirrhosis Undergoing Liver Transplantation. Gastroenterology. 2006;130(4):1135&#x02013;43.<pub-id pub-id-type="pmid">16618408</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Latt</surname><given-names>NL</given-names></name><name><surname>Niazi</surname><given-names>M</given-names></name><name><surname>Pyrsopoulos</surname><given-names>NT</given-names></name></person-group><article-title>Liver transplant allocation policies and outcomes in United States: A comprehensive review</article-title><source>World J Methodol</source><year>2022</year><volume>12</volume><issue>1</issue><fpage>32</fpage><lpage>42</lpage><?supplied-pmid 35117980?><pub-id pub-id-type="pmid">35117980</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Latt NL, Niazi M, Pyrsopoulos NT. Liver transplant allocation policies and outcomes in United States: A comprehensive review. World J Methodol. 2022;12(1):32&#x02013;42.<pub-id pub-id-type="pmid">35117980</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Cullaro</surname><given-names>G</given-names></name><name><surname>Sarkar</surname><given-names>M</given-names></name><name><surname>Lai</surname><given-names>JC</given-names></name></person-group><article-title>Sex-based disparities in delisting for being "too sick" for liver transplantation</article-title><source>Am J Transplant</source><year>2018</year><volume>18</volume><issue>5</issue><fpage>1214</fpage><lpage>1219</lpage><?supplied-pmid 29194969?><pub-id pub-id-type="pmid">29194969</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Cullaro G, Sarkar M, Lai JC. Sex-based disparities in delisting for being &#x0201c;too sick&#x0201d; for liver transplantation. Am J Transplant. 2018;18(5):1214&#x02013;9.<pub-id pub-id-type="pmid">29194969</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>AM</given-names></name><name><surname>Heimbach</surname><given-names>JK</given-names></name><name><surname>Larson</surname><given-names>JJ</given-names></name><name><surname>Mara</surname><given-names>KC</given-names></name><name><surname>Kim</surname><given-names>WR</given-names></name><name><surname>Kamath</surname><given-names>PS</given-names></name><etal/></person-group><article-title>Reduced Access to Liver Transplantation in Women: Role of Height, MELD Exception Scores, and Renal Function Underestimation</article-title><source>Transplantation</source><year>2018</year><volume>102</volume><issue>10</issue><fpage>1710</fpage><lpage>1716</lpage><?supplied-pmid 29620614?><pub-id pub-id-type="pmid">29620614</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Allen AM, Heimbach JK, Larson JJ, Mara KC, Kim WR, Kamath PS, et al. Reduced Access to Liver Transplantation in Women: Role of Height, MELD Exception Scores, and Renal Function Underestimation. Transplantation. 2018;102(10):1710&#x02013;6.<pub-id pub-id-type="pmid">29620614</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Bernardi</surname><given-names>M</given-names></name><name><surname>Gitto</surname><given-names>S</given-names></name><name><surname>Biselli</surname><given-names>M</given-names></name></person-group><article-title>The MELD score in patients awaiting liver transplant: Strengths and weaknesses</article-title><source>J Hepatol</source><year>2011</year><volume>54</volume><issue>6</issue><fpage>1297</fpage><lpage>1306</lpage><?supplied-pmid 21145851?><pub-id pub-id-type="pmid">21145851</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Bernardi M, Gitto S, Biselli M. The MELD score in patients awaiting liver transplant: Strengths and weaknesses. J Hepatol. 2011;54(6):1297&#x02013;306.<pub-id pub-id-type="pmid">21145851</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>WR</given-names></name><name><surname>Mannalithara</surname><given-names>A</given-names></name><name><surname>Heimbach</surname><given-names>JK</given-names></name><name><surname>Kamath</surname><given-names>PS</given-names></name><name><surname>Asrani</surname><given-names>SK</given-names></name><name><surname>Biggins</surname><given-names>SW</given-names></name><etal/></person-group><article-title>MELD 3.0: the model for end-stage liver disease updated for the modern Era</article-title><source>Gastroenterology</source><year>2021</year><volume>161</volume><issue>6</issue><fpage>1887</fpage><lpage>95.e4</lpage><?supplied-pmid 34481845?><pub-id pub-id-type="pmid">34481845</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Kim WR, Mannalithara A, Heimbach JK, Kamath PS, Asrani SK, Biggins SW, et al. MELD 3.0: the model for end-stage liver disease updated for the modern Era. Gastroenterology. 2021;161(6):1887-95.e4.<pub-id pub-id-type="pmid">34481845</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Samuel</surname><given-names>D</given-names></name><name><surname>De Martin</surname><given-names>E</given-names></name><name><surname>Berg</surname><given-names>T</given-names></name><name><surname>Berenguer</surname><given-names>M</given-names></name><name><surname>Burra</surname><given-names>P</given-names></name><name><surname>Fondevila</surname><given-names>C</given-names></name><etal/></person-group><article-title>EASL Clinical Practice Guidelines on liver transplantation</article-title><source>J Hepatol</source><year>2024</year><volume>81</volume><issue>6</issue><fpage>1040</fpage><lpage>1086</lpage><pub-id pub-id-type="pmid">39487043</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Samuel D, De Martin E, Berg T, Berenguer M, Burra P, Fondevila C, et al. EASL Clinical Practice Guidelines on liver transplantation. J Hepatol. 2024;81(6):1040&#x02013;86.<pub-id pub-id-type="pmid">39487043</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><mixed-citation publication-type="other">Rodr&#x000ed;guez-Per&#x000e1;lvarez ML, de la Rosa G, G&#x000f3;mez-Orellana AM, Aguilera MV, Pascual Vicente T, Pereira S, et al. GEMA-Na and MELD 3.0 severity scores to address sex disparities for accessing liver transplantation: a nationwide retrospective cohort study. EClinicalMedicine. 2024;74.</mixed-citation></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Cho</surname><given-names>YJ</given-names></name><name><surname>Choe</surname><given-names>WH</given-names></name><name><surname>Kwon</surname><given-names>SY</given-names></name><name><surname>Yoo</surname><given-names>BC</given-names></name></person-group><article-title>Model for end-stage liver disease-3.0 vs. model for end-stage liver disease-sodium: mortality prediction in Korea</article-title><source>Korean J Intern Med.</source><year>2024</year><volume>39</volume><issue>2</issue><fpage>248</fpage><lpage>260</lpage><?supplied-pmid 38296843?><pub-id pub-id-type="pmid">38296843</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Kim JH, Cho YJ, Choe WH, Kwon SY, Yoo BC. Model for end-stage liver disease-3.0 vs. model for end-stage liver disease-sodium: mortality prediction in Korea. Korean J Intern Med. 2024;39(2):248&#x02013;60.<pub-id pub-id-type="pmid">38296843</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><mixed-citation publication-type="other">Lin H-Y, Loi PL, Ng J, Shen L, Teo W-Q, Chung A, et al. MELD3.0 is superior to MELDNa and MELD for prediction of mortality in patients with cirrhosis: An external validation in a multi-ethnic population. JGH Open. 2024;8(6).</mixed-citation></ref><ref id="CR55"><label>55.</label><mixed-citation publication-type="other">D'Amico G, Perricone G, Morabito A, Latteri F, Fil&#x000ec; D, Affronti A, et al. Model for end stage liver disease for prediction of mortality in people with cirrhosis. Cochrane Database of Systematic Reviews 2021. Issue 1. Art. No.: CD013849. 10.1002/14651858.CD013849.</mixed-citation></ref><ref id="CR56"><label>56.</label><mixed-citation publication-type="other">Jophlin LL, Singal AK, Bataller R, Wong RJ, Sauer BG, Terrault NA, et al. ACG Clinical Guideline: Alcohol-Associated Liver Disease. Official journal of the American College of Gastroenterology | ACG. 2024;119(1).</mixed-citation></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Forrest</surname><given-names>EH</given-names></name><name><surname>Atkinson</surname><given-names>SR</given-names></name><name><surname>Richardson</surname><given-names>P</given-names></name><name><surname>Masson</surname><given-names>S</given-names></name><name><surname>Ryder</surname><given-names>S</given-names></name><name><surname>Thursz</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Application of prognostic scores in the STOPAH trial: Discriminant function is no longer the optimal scoring system in alcoholic hepatitis</article-title><source>J Hepatol</source><year>2018</year><volume>68</volume><issue>3</issue><fpage>511</fpage><lpage>518</lpage><?supplied-pmid 29175535?><pub-id pub-id-type="pmid">29175535</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Forrest EH, Atkinson SR, Richardson P, Masson S, Ryder S, Thursz MR, et al. Application of prognostic scores in the STOPAH trial: Discriminant function is no longer the optimal scoring system in alcoholic hepatitis. J Hepatol. 2018;68(3):511&#x02013;8.<pub-id pub-id-type="pmid">29175535</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><mixed-citation publication-type="other">Minich A, Arisar FAQ, Shaikh NS, Herman L, Azhie A, Orchanian-Cheff A, et al. Predictors of patient survival following liver transplant in non-alcoholic steatohepatitis: A systematic review and meta-analysis. EClinicalMedicine. 2022;50.</mixed-citation></ref><ref id="CR59"><label>59.</label><mixed-citation publication-type="other">Turner EL, Dobson JE, Pocock SJ. Categorisation of continuous risk factors in epidemiological publications: a survey of current practice. Epidemiol Perspect Innov. 2010;7.</mixed-citation></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Paik</surname><given-names>JM</given-names></name><name><surname>Golabi</surname><given-names>P</given-names></name><name><surname>Younossi</surname><given-names>Y</given-names></name><name><surname>Mishra</surname><given-names>A</given-names></name><name><surname>Younossi</surname><given-names>ZM</given-names></name></person-group><article-title>Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD</article-title><source>Hepatology</source><year>2020</year><volume>72</volume><issue>5</issue><fpage>1605</fpage><lpage>1616</lpage><?supplied-pmid 32043613?><pub-id pub-id-type="pmid">32043613</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD. Hepatology. 2020;72(5):1605&#x02013;16.<pub-id pub-id-type="pmid">32043613</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>LA</given-names></name><name><surname>Roberts</surname><given-names>SK</given-names></name><name><surname>Strasser</surname><given-names>SI</given-names></name><name><surname>Mahady</surname><given-names>SE</given-names></name><name><surname>Powell</surname><given-names>E</given-names></name><name><surname>Estes</surname><given-names>C</given-names></name><etal/></person-group><article-title>Nonalcoholic fatty liver disease burden: Australia, 2019&#x02013;2030</article-title><source>Journal of Gastroenterology and Hepatology.</source><year>2020</year><volume>35</volume><issue>9</issue><fpage>1628</fpage><lpage>35</lpage><?supplied-pmid 32048317?><pub-id pub-id-type="pmid">32048317</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Adams LA, Roberts SK, Strasser SI, Mahady SE, Powell E, Estes C, et al. Nonalcoholic fatty liver disease burden: Australia, 2019&#x02013;2030. Journal of Gastroenterology and Hepatology. 2020;35(9):1628&#x02013;35.<pub-id pub-id-type="pmid">32048317</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenstengle</surname><given-names>C</given-names></name><name><surname>Serper</surname><given-names>M</given-names></name><name><surname>Asrani</surname><given-names>SK</given-names></name><name><surname>Bittermann</surname><given-names>T</given-names></name><name><surname>Du</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>T-W</given-names></name><etal/></person-group><article-title>Variation in intention-to-treat survival by MELD subtypes: All models created for end-stage liver disease are not equal</article-title><source>J Hepatol</source><year>2025</year><volume>82</volume><issue>2</issue><fpage>268</fpage><lpage>276</lpage><?supplied-pmid 39181212?><pub-id pub-id-type="pmid">39181212</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Rosenstengle C, Serper M, Asrani SK, Bittermann T, Du J, Ma T-W, et al. Variation in intention-to-treat survival by MELD subtypes: All models created for end-stage liver disease are not equal. J Hepatol. 2025;82(2):268&#x02013;76.<pub-id pub-id-type="pmid">39181212</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Di Cola</surname><given-names>S</given-names></name><name><surname>D&#x02019;Amico</surname><given-names>G</given-names></name><name><surname>Caraceni</surname><given-names>P</given-names></name><name><surname>Schepis</surname><given-names>F</given-names></name><name><surname>Loredana</surname><given-names>S</given-names></name><name><surname>Lampertico</surname><given-names>P</given-names></name><etal/></person-group><article-title>Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis</article-title><source>J Hepatol</source><year>2024</year><volume>81</volume><issue>4</issue><fpage>641</fpage><lpage>650</lpage><?supplied-pmid 38782120?><pub-id pub-id-type="pmid">38782120</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Di Cola S, D&#x02019;Amico G, Caraceni P, Schepis F, Loredana S, Lampertico P, et al. Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis. J Hepatol. 2024;81(4):641&#x02013;50.<pub-id pub-id-type="pmid">38782120</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Lattanzi</surname><given-names>B</given-names></name><name><surname>Nardelli</surname><given-names>S</given-names></name><name><surname>Pigliacelli</surname><given-names>A</given-names></name><name><surname>Di Cola</surname><given-names>S</given-names></name><name><surname>Farcomeni</surname><given-names>A</given-names></name><name><surname>D'Ambrosio</surname><given-names>D</given-names></name><etal/></person-group><article-title>The additive value of sarcopenia, myosteatosis and hepatic encephalopathy in the predictivity of model for end-stage liver disease</article-title><source>Dig Liver Dis</source><year>2019</year><volume>51</volume><issue>11</issue><fpage>1508</fpage><lpage>1512</lpage><?supplied-pmid 31601536?><pub-id pub-id-type="pmid">31601536</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Lattanzi B, Nardelli S, Pigliacelli A, Di Cola S, Farcomeni A, D&#x02019;Ambrosio D, et al. The additive value of sarcopenia, myosteatosis and hepatic encephalopathy in the predictivity of model for end-stage liver disease. Dig Liver Dis. 2019;51(11):1508&#x02013;12.<pub-id pub-id-type="pmid">31601536</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>van Vugt</surname><given-names>JLA</given-names></name><name><surname>Levolger</surname><given-names>S</given-names></name><name><surname>de Bruin</surname><given-names>RWF</given-names></name><name><surname>van Rosmalen</surname><given-names>J</given-names></name><name><surname>Metselaar</surname><given-names>HJ</given-names></name><name><surname>Ijzermans</surname><given-names>JNM</given-names></name></person-group><article-title>Systematic Review and Meta-Analysis of the Impact of Computed Tomography-Assessed Skeletal Muscle Mass on Outcome in Patients Awaiting or Undergoing Liver Transplantation</article-title><source>Am J Transplant</source><year>2016</year><volume>16</volume><issue>8</issue><fpage>2277</fpage><lpage>2292</lpage><?supplied-pmid 26813115?><pub-id pub-id-type="pmid">26813115</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">van Vugt JLA, Levolger S, de Bruin RWF, van Rosmalen J, Metselaar HJ, Ijzermans JNM. Systematic Review and Meta-Analysis of the Impact of Computed Tomography-Assessed Skeletal Muscle Mass on Outcome in Patients Awaiting or Undergoing Liver Transplantation. Am J Transplant. 2016;16(8):2277&#x02013;92.<pub-id pub-id-type="pmid">26813115</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Tantai</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yeo</surname><given-names>YH</given-names></name><name><surname>Praktiknjo</surname><given-names>M</given-names></name><name><surname>Mauro</surname><given-names>E</given-names></name><name><surname>Hamaguchi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysis</article-title><source>J Hepatol</source><year>2022</year><volume>76</volume><issue>3</issue><fpage>588</fpage><lpage>599</lpage><?supplied-pmid 34785325?><pub-id pub-id-type="pmid">34785325</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Tantai X, Liu Y, Yeo YH, Praktiknjo M, Mauro E, Hamaguchi Y, et al. Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysis. J Hepatol. 2022;76(3):588&#x02013;99.<pub-id pub-id-type="pmid">34785325</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Biggins</surname><given-names>SW</given-names></name><name><surname>Kim</surname><given-names>WR</given-names></name><name><surname>Terrault</surname><given-names>NA</given-names></name><name><surname>Saab</surname><given-names>S</given-names></name><name><surname>Balan</surname><given-names>V</given-names></name><name><surname>Schiano</surname><given-names>T</given-names></name><etal/></person-group><article-title>Evidence-Based Incorporation of Serum Sodium Concentration Into MELD</article-title><source>Gastroenterology</source><year>2006</year><volume>130</volume><issue>6</issue><fpage>1652</fpage><lpage>1660</lpage><?supplied-pmid 16697729?><pub-id pub-id-type="pmid">16697729</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, et al. Evidence-Based Incorporation of Serum Sodium Concentration Into MELD. Gastroenterology. 2006;130(6):1652&#x02013;60.<pub-id pub-id-type="pmid">16697729</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Dawwas</surname><given-names>MF</given-names></name><name><surname>Lewsey</surname><given-names>JD</given-names></name><name><surname>Neuberger</surname><given-names>JM</given-names></name><name><surname>Gimson</surname><given-names>AE</given-names></name></person-group><article-title>The impact of serum sodium concentration on mortality after liver transplantation: a cohort multicenter study</article-title><source>Liver Transpl</source><year>2007</year><volume>13</volume><issue>8</issue><fpage>1115</fpage><lpage>1124</lpage><?supplied-pmid 17663412?><pub-id pub-id-type="pmid">17663412</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Dawwas MF, Lewsey JD, Neuberger JM, Gimson AE. The impact of serum sodium concentration on mortality after liver transplantation: a cohort multicenter study. Liver Transpl. 2007;13(8):1115&#x02013;24.<pub-id pub-id-type="pmid">17663412</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Barber</surname><given-names>K</given-names></name><name><surname>Madden</surname><given-names>S</given-names></name><name><surname>Allen</surname><given-names>J</given-names></name><name><surname>Collett</surname><given-names>D</given-names></name><name><surname>Neuberger</surname><given-names>J</given-names></name><name><surname>Gimson</surname><given-names>A</given-names></name></person-group><article-title>Elective liver transplant list mortality: development of a United Kingdom end-stage liver disease score</article-title><source>Transplantation</source><year>2011</year><volume>92</volume><issue>4</issue><fpage>469</fpage><lpage>476</lpage><?supplied-pmid 21775931?><pub-id pub-id-type="pmid">21775931</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Barber K, Madden S, Allen J, Collett D, Neuberger J, Gimson A. Elective liver transplant list mortality: development of a United Kingdom end-stage liver disease score. Transplantation. 2011;92(4):469&#x02013;76.<pub-id pub-id-type="pmid">21775931</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Neuberger</surname><given-names>J</given-names></name><name><surname>Gimson</surname><given-names>A</given-names></name><name><surname>Davies</surname><given-names>M</given-names></name><name><surname>Akyol</surname><given-names>M</given-names></name><name><surname>O'Grady</surname><given-names>J</given-names></name><name><surname>Burroughs</surname><given-names>A</given-names></name><etal/></person-group><article-title>Selection of patients for liver transplantation and allocation of donated livers in the UK</article-title><source>Gut</source><year>2008</year><volume>57</volume><issue>2</issue><fpage>252</fpage><lpage>257</lpage><?supplied-pmid 17895356?><pub-id pub-id-type="pmid">17895356</pub-id>
</element-citation><mixed-citation id="mc-CR70" publication-type="journal">Neuberger J, Gimson A, Davies M, Akyol M, O&#x02019;Grady J, Burroughs A, et al. Selection of patients for liver transplantation and allocation of donated livers in the UK. Gut. 2008;57(2):252&#x02013;7.<pub-id pub-id-type="pmid">17895356</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Millson</surname><given-names>C</given-names></name><name><surname>Considine</surname><given-names>A</given-names></name><name><surname>Cramp</surname><given-names>ME</given-names></name><name><surname>Holt</surname><given-names>A</given-names></name><name><surname>Hubscher</surname><given-names>S</given-names></name><name><surname>Hutchinson</surname><given-names>J</given-names></name><etal/></person-group><article-title>Adult liver transplantation: A UK clinical guideline - part 1: pre-operation</article-title><source>Frontline Gastroenterol</source><year>2020</year><volume>11</volume><issue>5</issue><fpage>375</fpage><lpage>384</lpage><?supplied-pmid 32879721?><pub-id pub-id-type="pmid">32879721</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Millson C, Considine A, Cramp ME, Holt A, Hubscher S, Hutchinson J, et al. Adult liver transplantation: A UK clinical guideline - part 1: pre-operation. Frontline Gastroenterol. 2020;11(5):375&#x02013;84.<pub-id pub-id-type="pmid">32879721</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Gimson</surname><given-names>A</given-names></name></person-group><article-title>Development of a UK liver transplantation selection and allocation scheme</article-title><source>Curr Opin Organ Transplant</source><year>2020</year><volume>25</volume><issue>2</issue><fpage>126</fpage><lpage>131</lpage><?supplied-pmid 32073485?><pub-id pub-id-type="pmid">32073485</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Gimson A. Development of a UK liver transplantation selection and allocation scheme. Curr Opin Organ Transplant. 2020;25(2):126&#x02013;31.<pub-id pub-id-type="pmid">32073485</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Rodr&#x000ed;guez-Per&#x000e1;lvarez</surname><given-names>ML</given-names></name><name><surname>G&#x000f3;mez-Orellana</surname><given-names>AM</given-names></name><name><surname>Majumdar</surname><given-names>A</given-names></name><name><surname>Bailey</surname><given-names>M</given-names></name><name><surname>McCaughan</surname><given-names>GW</given-names></name><name><surname>Gow</surname><given-names>P</given-names></name><etal/></person-group><article-title>Development and validation of the Gender-Equity Model for Liver Allocation (GEMA) to prioritise candidates for liver transplantation: a cohort study</article-title><source>Lancet Gastroenterol Hepatol</source><year>2023</year><volume>8</volume><issue>3</issue><fpage>242</fpage><lpage>252</lpage><?supplied-pmid 36528041?><pub-id pub-id-type="pmid">36528041</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">Rodr&#x000ed;guez-Per&#x000e1;lvarez ML, G&#x000f3;mez-Orellana AM, Majumdar A, Bailey M, McCaughan GW, Gow P, et al. Development and validation of the Gender-Equity Model for Liver Allocation (GEMA) to prioritise candidates for liver transplantation: a cohort study. Lancet Gastroenterol Hepatol. 2023;8(3):242&#x02013;52.<pub-id pub-id-type="pmid">36528041</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Cholongitas</surname><given-names>E</given-names></name><name><surname>Burroughs</surname><given-names>AK</given-names></name></person-group><article-title>The evolution in the prioritization for liver transplantation</article-title><source>Ann Gastroenterol</source><year>2012</year><volume>25</volume><issue>1</issue><fpage>6</fpage><lpage>13</lpage><?supplied-pmid 24713804?><pub-id pub-id-type="pmid">24713804</pub-id>
</element-citation><mixed-citation id="mc-CR74" publication-type="journal">Cholongitas E, Burroughs AK. The evolution in the prioritization for liver transplantation. Ann Gastroenterol. 2012;25(1):6&#x02013;13.<pub-id pub-id-type="pmid">24713804</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name><surname>Habib</surname><given-names>S</given-names></name><name><surname>Berk</surname><given-names>B</given-names></name><name><surname>Chang</surname><given-names>CC</given-names></name><name><surname>Demetris</surname><given-names>AJ</given-names></name><name><surname>Fontes</surname><given-names>P</given-names></name><name><surname>Dvorchik</surname><given-names>I</given-names></name><etal/></person-group><article-title>MELD and prediction of post-liver transplantation survival</article-title><source>Liver Transpl</source><year>2006</year><volume>12</volume><issue>3</issue><fpage>440</fpage><lpage>447</lpage><?supplied-pmid 16498643?><pub-id pub-id-type="pmid">16498643</pub-id>
</element-citation><mixed-citation id="mc-CR75" publication-type="journal">Habib S, Berk B, Chang CC, Demetris AJ, Fontes P, Dvorchik I, et al. MELD and prediction of post-liver transplantation survival. Liver Transpl. 2006;12(3):440&#x02013;7.<pub-id pub-id-type="pmid">16498643</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><mixed-citation publication-type="other">Klein KB, Stafinski TD, Menon D. Predicting Survival after Liver Transplantation Based on Pre-Transplant MELD Score: a Systematic Review of the Literature. PLoS ONE. 2013;8(12).</mixed-citation></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name><surname>Moreau</surname><given-names>R</given-names></name><name><surname>Jalan</surname><given-names>R</given-names></name><name><surname>Gines</surname><given-names>P</given-names></name><name><surname>Pavesi</surname><given-names>M</given-names></name><name><surname>Angeli</surname><given-names>P</given-names></name><name><surname>Cordoba</surname><given-names>J</given-names></name><etal/></person-group><article-title>Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis</article-title><source>Gastroenterology</source><year>2013</year><volume>144</volume><issue>7</issue><fpage>1426</fpage><lpage>37, 37.e1-9</lpage><?supplied-pmid 23474284?><pub-id pub-id-type="pmid">23474284</pub-id>
</element-citation><mixed-citation id="mc-CR77" publication-type="journal">Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426&#x02013;37, 37.e1-9.<pub-id pub-id-type="pmid">23474284</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>JL</given-names></name><name><surname>Moreno</surname><given-names>R</given-names></name><name><surname>Takala</surname><given-names>J</given-names></name><name><surname>Willatts</surname><given-names>S</given-names></name><name><surname>De Mendon&#x000e7;a</surname><given-names>A</given-names></name><name><surname>Bruining</surname><given-names>H</given-names></name><etal/></person-group><article-title>The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine</article-title><source>Intensive Care Med.</source><year>1996</year><volume>22</volume><issue>7</issue><fpage>707</fpage><lpage>10</lpage><?supplied-pmid 8844239?><pub-id pub-id-type="pmid">8844239</pub-id>
</element-citation><mixed-citation id="mc-CR78" publication-type="journal">Vincent JL, Moreno R, Takala J, Willatts S, De Mendon&#x000e7;a A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707&#x02013;10.<pub-id pub-id-type="pmid">8844239</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name><surname>Singer</surname><given-names>M</given-names></name><name><surname>Deutschman</surname><given-names>CS</given-names></name><name><surname>Seymour</surname><given-names>CW</given-names></name><name><surname>Shankar-Hari</surname><given-names>M</given-names></name><name><surname>Annane</surname><given-names>D</given-names></name><name><surname>Bauer</surname><given-names>M</given-names></name><etal/></person-group><article-title>The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)</article-title><source>JAMA</source><year>2016</year><volume>315</volume><issue>8</issue><fpage>801</fpage><lpage>810</lpage><?supplied-pmid 26903338?><pub-id pub-id-type="pmid">26903338</pub-id>
</element-citation><mixed-citation id="mc-CR79" publication-type="journal">Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801&#x02013;10.<pub-id pub-id-type="pmid">26903338</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name><surname>Lambden</surname><given-names>S</given-names></name><name><surname>Laterre</surname><given-names>PF</given-names></name><name><surname>Levy</surname><given-names>MM</given-names></name><name><surname>Francois</surname><given-names>B</given-names></name></person-group><article-title>The SOFA score&#x02014;development, utility and challenges of accurate assessment in clinical trials</article-title><source>Crit Care</source><year>2019</year><volume>23</volume><issue>1</issue><fpage>374</fpage><?supplied-pmid 31775846?><pub-id pub-id-type="pmid">31775846</pub-id>
</element-citation><mixed-citation id="mc-CR80" publication-type="journal">Lambden S, Laterre PF, Levy MM, Francois B. The SOFA score&#x02014;development, utility and challenges of accurate assessment in clinical trials. Crit Care. 2019;23(1):374.<pub-id pub-id-type="pmid">31775846</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name><surname>Jalan</surname><given-names>R</given-names></name><name><surname>Saliba</surname><given-names>F</given-names></name><name><surname>Pavesi</surname><given-names>M</given-names></name><name><surname>Amoros</surname><given-names>A</given-names></name><name><surname>Moreau</surname><given-names>R</given-names></name><name><surname>Gin&#x000e8;s</surname><given-names>P</given-names></name><etal/></person-group><article-title>Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure</article-title><source>J Hepatol</source><year>2014</year><volume>61</volume><issue>5</issue><fpage>1038</fpage><lpage>1047</lpage><?supplied-pmid 24950482?><pub-id pub-id-type="pmid">24950482</pub-id>
</element-citation><mixed-citation id="mc-CR81" publication-type="journal">Jalan R, Saliba F, Pavesi M, Amoros A, Moreau R, Gin&#x000e8;s P, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol. 2014;61(5):1038&#x02013;47.<pub-id pub-id-type="pmid">24950482</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name><surname>Mahmud</surname><given-names>N</given-names></name><name><surname>Kaplan</surname><given-names>DE</given-names></name><name><surname>Taddei</surname><given-names>TH</given-names></name><name><surname>Goldberg</surname><given-names>DS</given-names></name></person-group><article-title>Incidence and mortality of acute-on-chronic liver failure using two definitions in patients with compensated cirrhosis</article-title><source>Hepatology</source><year>2019</year><volume>69</volume><issue>5</issue><fpage>2150</fpage><lpage>2163</lpage><?supplied-pmid 30615211?><pub-id pub-id-type="pmid">30615211</pub-id>
</element-citation><mixed-citation id="mc-CR82" publication-type="journal">Mahmud N, Kaplan DE, Taddei TH, Goldberg DS. Incidence and mortality of acute-on-chronic liver failure using two definitions in patients with compensated cirrhosis. Hepatology. 2019;69(5):2150&#x02013;63.<pub-id pub-id-type="pmid">30615211</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name><surname>Sarin</surname><given-names>SK</given-names></name><name><surname>Choudhury</surname><given-names>A</given-names></name><name><surname>Sharma</surname><given-names>MK</given-names></name><name><surname>Maiwall</surname><given-names>R</given-names></name><name><surname>Al Mahtab</surname><given-names>M</given-names></name><name><surname>Rahman</surname><given-names>S</given-names></name><etal/></person-group><article-title>Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update</article-title><source>Hepatol Int</source><year>2019</year><volume>13</volume><issue>4</issue><fpage>353</fpage><lpage>390</lpage><?supplied-pmid 31172417?><pub-id pub-id-type="pmid">31172417</pub-id>
</element-citation><mixed-citation id="mc-CR83" publication-type="journal">Sarin SK, Choudhury A, Sharma MK, Maiwall R, Al Mahtab M, Rahman S, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019;13(4):353&#x02013;90.<pub-id pub-id-type="pmid">31172417</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name><surname>Mezzano</surname><given-names>G</given-names></name><name><surname>Juanola</surname><given-names>A</given-names></name><name><surname>Cardenas</surname><given-names>A</given-names></name><name><surname>Mezey</surname><given-names>E</given-names></name><name><surname>Hamilton</surname><given-names>JP</given-names></name><name><surname>Pose</surname><given-names>E</given-names></name><etal/></person-group><article-title>Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis</article-title><source>Gut</source><year>2022</year><volume>71</volume><issue>1</issue><fpage>148</fpage><lpage>155</lpage><?supplied-pmid 33436495?><pub-id pub-id-type="pmid">33436495</pub-id>
</element-citation><mixed-citation id="mc-CR84" publication-type="journal">Mezzano G, Juanola A, Cardenas A, Mezey E, Hamilton JP, Pose E, et al. Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis. Gut. 2022;71(1):148&#x02013;55.<pub-id pub-id-type="pmid">33436495</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name><surname>Abdallah</surname><given-names>MA</given-names></name><name><surname>Kuo</surname><given-names>YF</given-names></name><name><surname>Asrani</surname><given-names>S</given-names></name><name><surname>Wong</surname><given-names>RJ</given-names></name><name><surname>Ahmed</surname><given-names>A</given-names></name><name><surname>Kwo</surname><given-names>P</given-names></name><etal/></person-group><article-title>Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality</article-title><source>J Hepatol</source><year>2021</year><volume>74</volume><issue>6</issue><fpage>1355</fpage><lpage>1361</lpage><?supplied-pmid 33326814?><pub-id pub-id-type="pmid">33326814</pub-id>
</element-citation><mixed-citation id="mc-CR85" publication-type="journal">Abdallah MA, Kuo YF, Asrani S, Wong RJ, Ahmed A, Kwo P, et al. Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality. J Hepatol. 2021;74(6):1355&#x02013;61.<pub-id pub-id-type="pmid">33326814</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Luo</surname><given-names>L</given-names></name><name><surname>Lei</surname><given-names>S</given-names></name><name><surname>Xiong</surname><given-names>T</given-names></name><name><surname>Long</surname><given-names>L</given-names></name><etal/></person-group><article-title>A prognostic model of acute-on-chronic liver failure based on sarcopenia</article-title><source>Hepatol Int</source><year>2022</year><volume>16</volume><issue>4</issue><fpage>964</fpage><lpage>972</lpage><?supplied-pmid 35771410?><pub-id pub-id-type="pmid">35771410</pub-id>
</element-citation><mixed-citation id="mc-CR86" publication-type="journal">Peng H, Zhang Q, Luo L, Lei S, Xiong T, Long L, et al. A prognostic model of acute-on-chronic liver failure based on sarcopenia. Hepatol Int. 2022;16(4):964&#x02013;72.<pub-id pub-id-type="pmid">35771410</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name><surname>Michelena</surname><given-names>J</given-names></name><name><surname>Altamirano</surname><given-names>J</given-names></name><name><surname>Abraldes</surname><given-names>JG</given-names></name><name><surname>Aff&#x000f2;</surname><given-names>S</given-names></name><name><surname>Morales-Ibanez</surname><given-names>O</given-names></name><name><surname>Sancho-Bru</surname><given-names>P</given-names></name><etal/></person-group><article-title>Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis</article-title><source>Hepatology</source><year>2015</year><volume>62</volume><issue>3</issue><fpage>762</fpage><lpage>772</lpage><?supplied-pmid 25761863?><pub-id pub-id-type="pmid">25761863</pub-id>
</element-citation><mixed-citation id="mc-CR87" publication-type="journal">Michelena J, Altamirano J, Abraldes JG, Aff&#x000f2; S, Morales-Ibanez O, Sancho-Bru P, et al. Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. Hepatology. 2015;62(3):762&#x02013;72.<pub-id pub-id-type="pmid">25761863</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><mixed-citation publication-type="other">Li H, Chen L-Y, Zhang N-N, Li S-T, Zeng B, Pavesi M, et al. Characteristics, diagnosis and prognosis of acute-on-chronic liver failure in cirrhosis associated to hepatitis B. Sci Rep. 2016;6(1).</mixed-citation></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name><surname>Jalan</surname><given-names>R</given-names></name><name><surname>Pavesi</surname><given-names>M</given-names></name><name><surname>Saliba</surname><given-names>F</given-names></name><name><surname>Amor&#x000f3;s</surname><given-names>A</given-names></name><name><surname>Fernandez</surname><given-names>J</given-names></name><name><surname>Holland-Fischer</surname><given-names>P</given-names></name><etal/></person-group><article-title>The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure</article-title><source>J Hepatol</source><year>2015</year><volume>62</volume><issue>4</issue><fpage>831</fpage><lpage>840</lpage><?supplied-pmid 25463539?><pub-id pub-id-type="pmid">25463539</pub-id>
</element-citation><mixed-citation id="mc-CR89" publication-type="journal">Jalan R, Pavesi M, Saliba F, Amor&#x000f3;s A, Fernandez J, Holland-Fischer P, et al. The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. J Hepatol. 2015;62(4):831&#x02013;40.<pub-id pub-id-type="pmid">25463539</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name><surname>Baldin</surname><given-names>C</given-names></name><name><surname>Piedade</surname><given-names>J</given-names></name><name><surname>Guimar&#x000e3;es</surname><given-names>L</given-names></name><name><surname>Victor</surname><given-names>L</given-names></name><name><surname>Duarte</surname><given-names>J</given-names></name><name><surname>Veiga</surname><given-names>Z</given-names></name><etal/></person-group><article-title>CLIF-C AD Score Predicts Development of Acute Decompensations and Survival in Hospitalized Cirrhotic Patients</article-title><source>Dig Dis Sci</source><year>2021</year><volume>66</volume><issue>12</issue><fpage>4525</fpage><lpage>4535</lpage><?supplied-pmid 33389350?><pub-id pub-id-type="pmid">33389350</pub-id>
</element-citation><mixed-citation id="mc-CR90" publication-type="journal">Baldin C, Piedade J, Guimar&#x000e3;es L, Victor L, Duarte J, Veiga Z, et al. CLIF-C AD Score Predicts Development of Acute Decompensations and Survival in Hospitalized Cirrhotic Patients. Dig Dis Sci. 2021;66(12):4525&#x02013;35.<pub-id pub-id-type="pmid">33389350</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name><surname>Sturm</surname><given-names>L</given-names></name><name><surname>Praktiknjo</surname><given-names>M</given-names></name><name><surname>Bettinger</surname><given-names>D</given-names></name><name><surname>Huber</surname><given-names>JP</given-names></name><name><surname>Volkwein</surname><given-names>L</given-names></name><name><surname>Schmidt</surname><given-names>A</given-names></name><etal/></person-group><article-title>Prognostic value of the CLIF-C AD score in patients with implantation of transjugular intrahepatic portosystemic Shunt</article-title><source>Hepatol Commun</source><year>2021</year><volume>5</volume><issue>4</issue><fpage>650</fpage><lpage>60</lpage><?supplied-pmid 33860123?><pub-id pub-id-type="pmid">33860123</pub-id>
</element-citation><mixed-citation id="mc-CR91" publication-type="journal">Sturm L, Praktiknjo M, Bettinger D, Huber JP, Volkwein L, Schmidt A, et al. Prognostic value of the CLIF-C AD score in patients with implantation of transjugular intrahepatic portosystemic Shunt. Hepatol Commun. 2021;5(4):650&#x02013;60.<pub-id pub-id-type="pmid">33860123</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>PK</given-names></name><name><surname>Geskus</surname><given-names>RB</given-names></name><name><surname>De Witte</surname><given-names>T</given-names></name><name><surname>Putter</surname><given-names>H</given-names></name></person-group><article-title>Competing risks in epidemiology: possibilities and pitfalls</article-title><source>Int J Epidemiol</source><year>2012</year><volume>41</volume><issue>3</issue><fpage>861</fpage><lpage>870</lpage><?supplied-pmid 22253319?><pub-id pub-id-type="pmid">22253319</pub-id>
</element-citation><mixed-citation id="mc-CR92" publication-type="journal">Andersen PK, Geskus RB, De Witte T, Putter H. Competing risks in epidemiology: possibilities and pitfalls. Int J Epidemiol. 2012;41(3):861&#x02013;70.<pub-id pub-id-type="pmid">22253319</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name><surname>Swift</surname><given-names>O</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Ramanarayanan</surname><given-names>S</given-names></name><name><surname>Umar</surname><given-names>H</given-names></name><name><surname>Laws</surname><given-names>KR</given-names></name><name><surname>Vilar</surname><given-names>E</given-names></name><etal/></person-group><article-title>Prevalence and outcomes of chronic liver disease in patients receiving dialysis: systematic review and meta-analysis</article-title><source>Clin Kidney J</source><year>2022</year><volume>15</volume><issue>4</issue><fpage>747</fpage><lpage>757</lpage><?supplied-pmid 35371444?><pub-id pub-id-type="pmid">35371444</pub-id>
</element-citation><mixed-citation id="mc-CR93" publication-type="journal">Swift O, Sharma S, Ramanarayanan S, Umar H, Laws KR, Vilar E, et al. Prevalence and outcomes of chronic liver disease in patients receiving dialysis: systematic review and meta-analysis. Clin Kidney J. 2022;15(4):747&#x02013;57.<pub-id pub-id-type="pmid">35371444</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Romeiro</surname><given-names>FG</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Philips</surname><given-names>CA</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Development and validation of modified Liaoning score for predicting the prognosis of liver cirrhosis: a retrospective, international multicenter, observational study</article-title><source>Expert Rev Gastroenterol Hepatol</source><year>2024</year><volume>18</volume><issue>1&#x02013;3</issue><fpage>121</fpage><lpage>128</lpage><?supplied-pmid 38362663?><pub-id pub-id-type="pmid">38362663</pub-id>
</element-citation><mixed-citation id="mc-CR94" publication-type="journal">Song X, Romeiro FG, Wang J, Yin Y, Philips CA, Yang X, et al. Development and validation of modified Liaoning score for predicting the prognosis of liver cirrhosis: a retrospective, international multicenter, observational study. Expert Rev Gastroenterol Hepatol. 2024;18(1&#x02013;3):121&#x02013;8.<pub-id pub-id-type="pmid">38362663</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name><surname>Minagawa</surname><given-names>M</given-names></name><name><surname>Ikai</surname><given-names>I</given-names></name><name><surname>Matsuyama</surname><given-names>Y</given-names></name><name><surname>Yamaoka</surname><given-names>Y</given-names></name><name><surname>Makuuchi</surname><given-names>M</given-names></name></person-group><article-title>Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan</article-title><source>Ann Surg</source><year>2007</year><volume>245</volume><issue>6</issue><fpage>909</fpage><lpage>922</lpage><?supplied-pmid 17522517?><pub-id pub-id-type="pmid">17522517</pub-id>
</element-citation><mixed-citation id="mc-CR95" publication-type="journal">Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg. 2007;245(6):909&#x02013;22.<pub-id pub-id-type="pmid">17522517</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>PJ</given-names></name><name><surname>Berhane</surname><given-names>S</given-names></name><name><surname>Kagebayashi</surname><given-names>C</given-names></name><name><surname>Satomura</surname><given-names>S</given-names></name><name><surname>Teng</surname><given-names>M</given-names></name><name><surname>Reeves</surname><given-names>HL</given-names></name><etal/></person-group><article-title>Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach&#x02014;The ALBI Grade</article-title><source>J Clin Oncol</source><year>2015</year><volume>33</volume><issue>6</issue><fpage>550</fpage><lpage>558</lpage><?supplied-pmid 25512453?><pub-id pub-id-type="pmid">25512453</pub-id>
</element-citation><mixed-citation id="mc-CR96" publication-type="journal">Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach&#x02014;The ALBI Grade. J Clin Oncol. 2015;33(6):550&#x02013;8.<pub-id pub-id-type="pmid">25512453</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name><surname>Hiraoka</surname><given-names>A</given-names></name><name><surname>Michitaka</surname><given-names>K</given-names></name><name><surname>Kumada</surname><given-names>T</given-names></name><name><surname>Izumi</surname><given-names>N</given-names></name><name><surname>Kadoya</surname><given-names>M</given-names></name><name><surname>Kokudo</surname><given-names>N</given-names></name><etal/></person-group><article-title>Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function</article-title><source>Liver Cancer</source><year>2017</year><volume>6</volume><issue>4</issue><fpage>325</fpage><lpage>336</lpage><?supplied-pmid 29234636?><pub-id pub-id-type="pmid">29234636</pub-id>
</element-citation><mixed-citation id="mc-CR97" publication-type="journal">Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, et al. Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. Liver Cancer. 2017;6(4):325&#x02013;36.<pub-id pub-id-type="pmid">29234636</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name><surname>Pinato</surname><given-names>DJ</given-names></name><name><surname>Sharma</surname><given-names>R</given-names></name><name><surname>Allara</surname><given-names>E</given-names></name><name><surname>Yen</surname><given-names>C</given-names></name><name><surname>Arizumi</surname><given-names>T</given-names></name><name><surname>Kubota</surname><given-names>K</given-names></name><etal/></person-group><article-title>The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma</article-title><source>J Hepatol</source><year>2017</year><volume>66</volume><issue>2</issue><fpage>338</fpage><lpage>346</lpage><?supplied-pmid 27677714?><pub-id pub-id-type="pmid">27677714</pub-id>
</element-citation><mixed-citation id="mc-CR98" publication-type="journal">Pinato DJ, Sharma R, Allara E, Yen C, Arizumi T, Kubota K, et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol. 2017;66(2):338&#x02013;46.<pub-id pub-id-type="pmid">27677714</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><mixed-citation publication-type="other">Demirtas CO, D&#x02019;Alessio A, Rimassa L, Sharma R, Pinato DJ. ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Rep. 2021;3(5).</mixed-citation></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name><surname>Kudo</surname><given-names>M</given-names></name><name><surname>Finn</surname><given-names>RS</given-names></name><name><surname>Cheng</surname><given-names>AL</given-names></name><name><surname>Zhu</surname><given-names>AX</given-names></name><name><surname>Ducreux</surname><given-names>M</given-names></name><name><surname>Galle</surname><given-names>PR</given-names></name><etal/></person-group><article-title>Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study</article-title><source>Liver Cancer</source><year>2023</year><volume>12</volume><issue>5</issue><fpage>479</fpage><lpage>493</lpage><?supplied-pmid 37901766?><pub-id pub-id-type="pmid">37901766</pub-id>
</element-citation><mixed-citation id="mc-CR100" publication-type="journal">Kudo M, Finn RS, Cheng AL, Zhu AX, Ducreux M, Galle PR, et al. Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study. Liver Cancer. 2023;12(5):479&#x02013;93.<pub-id pub-id-type="pmid">37901766</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>G</given-names></name><name><surname>Majeed</surname><given-names>A</given-names></name><name><surname>Dev</surname><given-names>A</given-names></name><name><surname>Eslick</surname><given-names>GD</given-names></name><name><surname>Pinato</surname><given-names>DJ</given-names></name><name><surname>Izumoto</surname><given-names>H</given-names></name><etal/></person-group><article-title>Clinical Utility of Albumin Bilirubin Grade as a Prognostic Marker in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: a Systematic Review and Meta-analysis</article-title><source>J Gastrointest Cancer</source><year>2023</year><volume>54</volume><issue>2</issue><fpage>420</fpage><lpage>432</lpage><?supplied-pmid 35635637?><pub-id pub-id-type="pmid">35635637</pub-id>
</element-citation><mixed-citation id="mc-CR101" publication-type="journal">Mishra G, Majeed A, Dev A, Eslick GD, Pinato DJ, Izumoto H, et al. Clinical Utility of Albumin Bilirubin Grade as a Prognostic Marker in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: a Systematic Review and Meta-analysis. J Gastrointest Cancer. 2023;54(2):420&#x02013;32.<pub-id pub-id-type="pmid">35635637</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><mixed-citation publication-type="other">Marasco G, Alemanni LV, Colecchia A, Festi D, Bazzoli F, Mazzella G, et al. Prognostic Value of the Albumin-Bilirubin Grade for the Prediction of Post-Hepatectomy Liver Failure: A Systematic Review and Meta-Analysis. J Clin Med. 2021;10(9).</mixed-citation></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name><surname>Boyer</surname><given-names>TD</given-names></name><name><surname>Haskal</surname><given-names>ZJ</given-names></name></person-group><article-title>The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: Update 2009</article-title><source>Hepatology.</source><year>2010</year><volume>51</volume><issue>1</issue><fpage>306-</fpage><?supplied-pmid 19902484?><pub-id pub-id-type="pmid">19902484</pub-id>
</element-citation><mixed-citation id="mc-CR103" publication-type="journal">Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: Update 2009. Hepatology. 2010;51(1):306-.<pub-id pub-id-type="pmid">19902484</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name><surname>Caraceni</surname><given-names>P</given-names></name><name><surname>Riggio</surname><given-names>O</given-names></name><name><surname>Angeli</surname><given-names>P</given-names></name><name><surname>Alessandria</surname><given-names>C</given-names></name><name><surname>Neri</surname><given-names>S</given-names></name><name><surname>Foschi</surname><given-names>FG</given-names></name><etal/></person-group><article-title>Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial</article-title><source>The Lancet</source><year>2018</year><volume>391</volume><issue>10138</issue><fpage>2417</fpage><lpage>2429</lpage></element-citation><mixed-citation id="mc-CR104" publication-type="journal">Caraceni P, Riggio O, Angeli P, Alessandria C, Neri S, Foschi FG, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. The Lancet. 2018;391(10138):2417&#x02013;29.</mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name><surname>Colombato</surname><given-names>L</given-names></name></person-group><article-title>The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in the Management of Portal Hypertension</article-title><source>J Clin Gastroenterol</source><year>2007</year><volume>41</volume><issue>Supplement 3</issue><fpage>S344</fpage><lpage>S351</lpage><?supplied-pmid 17975487?><pub-id pub-id-type="pmid">17975487</pub-id>
</element-citation><mixed-citation id="mc-CR105" publication-type="journal">Colombato L. The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in the Management of Portal Hypertension. J Clin Gastroenterol. 2007;41(Supplement 3):S344&#x02013;51.<pub-id pub-id-type="pmid">17975487</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name><surname>Angermayr</surname><given-names>B</given-names></name></person-group><source>Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents</source><year>2003</year><volume>38</volume><issue>4</issue><fpage>1043</fpage><lpage>1050</lpage></element-citation><mixed-citation id="mc-CR106" publication-type="journal">Angermayr B. Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents. 2003;38(4):1043&#x02013;50.</mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name><surname>Triantafyllou</surname><given-names>T</given-names></name><name><surname>Aggarwal</surname><given-names>P</given-names></name><name><surname>Gupta</surname><given-names>E</given-names></name><name><surname>Svetanoff</surname><given-names>WJ</given-names></name><name><surname>Bhirud</surname><given-names>DP</given-names></name><name><surname>Singhal</surname><given-names>S</given-names></name></person-group><article-title>Polytetrafluoroethylene-Covered Stent Graft Versus Bare Stent in Transjugular Intrahepatic Portosystemic Shunt: Systematic Review and Meta-Analysis</article-title><source>J Laparoendosc Adv Surg Tech</source><year>2018</year><volume>28</volume><issue>7</issue><fpage>867</fpage><lpage>879</lpage></element-citation><mixed-citation id="mc-CR107" publication-type="journal">Triantafyllou T, Aggarwal P, Gupta E, Svetanoff WJ, Bhirud DP, Singhal S. Polytetrafluoroethylene-Covered Stent Graft Versus Bare Stent in Transjugular Intrahepatic Portosystemic Shunt: Systematic Review and Meta-Analysis. J Laparoendosc Adv Surg Tech. 2018;28(7):867&#x02013;79.</mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000fc;ttner</surname><given-names>L</given-names></name><name><surname>Aigner</surname><given-names>A</given-names></name><name><surname>Pick</surname><given-names>L</given-names></name><name><surname>Brittinger</surname><given-names>J</given-names></name><name><surname>Steib</surname><given-names>CJ</given-names></name><name><surname>B&#x000f6;ning</surname><given-names>G</given-names></name><etal/></person-group><article-title>25 years of experience with transjugular intrahepatic portosystemic shunt (TIPS): changes in patient selection and procedural aspects</article-title><source>Insights Imaging</source><year>2022</year><volume>13</volume><issue>1</issue><fpage>73</fpage><?supplied-pmid 35416547?><pub-id pub-id-type="pmid">35416547</pub-id>
</element-citation><mixed-citation id="mc-CR108" publication-type="journal">B&#x000fc;ttner L, Aigner A, Pick L, Brittinger J, Steib CJ, B&#x000f6;ning G, et al. 25 years of experience with transjugular intrahepatic portosystemic shunt (TIPS): changes in patient selection and procedural aspects. Insights Imaging. 2022;13(1):73.<pub-id pub-id-type="pmid">35416547</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name><surname>Bettinger</surname><given-names>D</given-names></name><name><surname>Sturm</surname><given-names>L</given-names></name><name><surname>Pfaff</surname><given-names>L</given-names></name><name><surname>Hahn</surname><given-names>F</given-names></name><name><surname>Kloeckner</surname><given-names>R</given-names></name><name><surname>Volkwein</surname><given-names>L</given-names></name><etal/></person-group><article-title>Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival</article-title><source>J Hepatol</source><year>2021</year><volume>74</volume><issue>6</issue><fpage>1362</fpage><lpage>1372</lpage><?supplied-pmid 33508376?><pub-id pub-id-type="pmid">33508376</pub-id>
</element-citation><mixed-citation id="mc-CR109" publication-type="journal">Bettinger D, Sturm L, Pfaff L, Hahn F, Kloeckner R, Volkwein L, et al. Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival. J Hepatol. 2021;74(6):1362&#x02013;72.<pub-id pub-id-type="pmid">33508376</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><mixed-citation publication-type="other">Chapin SE, Goldberg DS, Kaplan DE, Mahmud N. External validation of the FIPS score for Post-TIPS mortality in a national veterans affairs cohort. Digest Dis Sci.&#x000a0;2022;67(9):4581-89.</mixed-citation></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>FIPS Score for Prediction of Survival After TIPS Placement: External Validation and Comparison With Traditional Risk Scores in a Cohort of Chinese Patients With Cirrhosis</article-title><source>AJR Am J Roentgenol</source><year>2022</year><volume>219</volume><issue>2</issue><fpage>255</fpage><lpage>267</lpage><?supplied-pmid 35138134?><pub-id pub-id-type="pmid">35138134</pub-id>
</element-citation><mixed-citation id="mc-CR111" publication-type="journal">Yang C, Chen Q, Zhou C, Liu J, Huang S, Wang Y, et al. FIPS Score for Prediction of Survival After TIPS Placement: External Validation and Comparison With Traditional Risk Scores in a Cohort of Chinese Patients With Cirrhosis. AJR Am J Roentgenol. 2022;219(2):255&#x02013;67.<pub-id pub-id-type="pmid">35138134</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><mixed-citation publication-type="other">Zhao Y, Wang Y, Xu J. Predictive accuracy comparison of prognostic scoring systems for survival in patients undergoing TIPS Placement: a systematic review and meta-analysis. Acad Radiol. 2023.</mixed-citation></ref><ref id="CR113"><label>113.</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Xiang</surname><given-names>T</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name></person-group><article-title>MELD 3.0 score for predicting survival in patients with cirrhosis after transjugular intrahepatic portosystemic shunt creation</article-title><source>Dig Dis Sci</source><year>2023</year><volume>68</volume><issue>7</issue><fpage>3185</fpage><lpage>3192</lpage><?supplied-pmid 36715817?><pub-id pub-id-type="pmid">36715817</pub-id>
</element-citation><mixed-citation id="mc-CR113" publication-type="journal">Song J, Wang X, Yan Y, Xiang T, Luo X. MELD 3.0 score for predicting survival in patients with cirrhosis after transjugular intrahepatic portosystemic shunt creation. Dig Dis Sci. 2023;68(7):3185&#x02013;92.<pub-id pub-id-type="pmid">36715817</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name><surname>Stockhoff</surname><given-names>L</given-names></name><name><surname>Schneider</surname><given-names>H</given-names></name><name><surname>Tergast</surname><given-names>TL</given-names></name><name><surname>Cornberg</surname><given-names>M</given-names></name><name><surname>Maasoumy</surname><given-names>B</given-names></name></person-group><article-title>Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?</article-title><source>J Hepatol</source><year>2021</year><volume>75</volume><issue>2</issue><fpage>487</fpage><lpage>489</lpage><?supplied-pmid 33716088?><pub-id pub-id-type="pmid">33716088</pub-id>
</element-citation><mixed-citation id="mc-CR114" publication-type="journal">Stockhoff L, Schneider H, Tergast TL, Cornberg M, Maasoumy B. Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS? J Hepatol. 2021;75(2):487&#x02013;9.<pub-id pub-id-type="pmid">33716088</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name><surname>Kalo</surname><given-names>E</given-names></name><name><surname>Sturm</surname><given-names>L</given-names></name><name><surname>Schultheiss</surname><given-names>M</given-names></name><name><surname>Moore</surname><given-names>O</given-names></name><name><surname>Kurup</surname><given-names>R</given-names></name><name><surname>Gahm</surname><given-names>C</given-names></name><etal/></person-group><article-title>The Freiburg Index of Post-TIPS Survival accurately predicts mortality in patients with acute decompensation of cirrhosis</article-title><source>Liver Int</source><year>2024</year><volume>44</volume><issue>12</issue><fpage>3229</fpage><lpage>3237</lpage><?supplied-pmid 39248164?><pub-id pub-id-type="pmid">39248164</pub-id>
</element-citation><mixed-citation id="mc-CR115" publication-type="journal">Kalo E, Sturm L, Schultheiss M, Moore O, Kurup R, Gahm C, et al. The Freiburg Index of Post-TIPS Survival accurately predicts mortality in patients with acute decompensation of cirrhosis. Liver Int. 2024;44(12):3229&#x02013;37.<pub-id pub-id-type="pmid">39248164</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name><surname>Delanaye</surname><given-names>P</given-names></name><name><surname>Cavalier</surname><given-names>E</given-names></name><name><surname>Pottel</surname><given-names>H</given-names></name></person-group><article-title>Serum creatinine: not so simple!</article-title><source>Nephron</source><year>2017</year><volume>136</volume><issue>4</issue><fpage>302</fpage><lpage>308</lpage><?supplied-pmid 28441651?><pub-id pub-id-type="pmid">28441651</pub-id>
</element-citation><mixed-citation id="mc-CR116" publication-type="journal">Delanaye P, Cavalier E, Pottel H. Serum creatinine: not so simple! Nephron. 2017;136(4):302&#x02013;8.<pub-id pub-id-type="pmid">28441651</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name><surname>Figueiredo</surname><given-names>FA</given-names></name><name><surname>Dickson</surname><given-names>ER</given-names></name><name><surname>Pasha</surname><given-names>TM</given-names></name><name><surname>Porayko</surname><given-names>MK</given-names></name><name><surname>Therneau</surname><given-names>TM</given-names></name><name><surname>Malinchoc</surname><given-names>M</given-names></name><etal/></person-group><article-title>Utility of standard nutritional parameters in detecting body cell mass depletion in patients with end-stage liver disease</article-title><source>Liver Transpl</source><year>2000</year><volume>6</volume><issue>5</issue><fpage>575</fpage><lpage>581</lpage><?supplied-pmid 10980056?><pub-id pub-id-type="pmid">10980056</pub-id>
</element-citation><mixed-citation id="mc-CR117" publication-type="journal">Figueiredo FA, Dickson ER, Pasha TM, Porayko MK, Therneau TM, Malinchoc M, et al. Utility of standard nutritional parameters in detecting body cell mass depletion in patients with end-stage liver disease. Liver Transpl. 2000;6(5):575&#x02013;81.<pub-id pub-id-type="pmid">10980056</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name><surname>Alessandria</surname><given-names>C</given-names></name><name><surname>Gaia</surname><given-names>S</given-names></name><name><surname>Marzano</surname><given-names>A</given-names></name><name><surname>Venon</surname><given-names>WD</given-names></name><name><surname>Fadda</surname><given-names>M</given-names></name><name><surname>Rizzetto</surname><given-names>M</given-names></name></person-group><article-title>Application of the model for end-stage liver disease score for transjugular intrahepatic portosystemic shunt in cirrhotic patients with refractory ascites and renal impairment</article-title><source>Eur J Gastroenterol Hepatol</source><year>2004</year><volume>16</volume><issue>6</issue><fpage>607</fpage><lpage>612</lpage><?supplied-pmid 15167164?><pub-id pub-id-type="pmid">15167164</pub-id>
</element-citation><mixed-citation id="mc-CR118" publication-type="journal">Alessandria C, Gaia S, Marzano A, Venon WD, Fadda M, Rizzetto M. Application of the model for end-stage liver disease score for transjugular intrahepatic portosystemic shunt in cirrhotic patients with refractory ascites and renal impairment. Eur J Gastroenterol Hepatol. 2004;16(6):607&#x02013;12.<pub-id pub-id-type="pmid">15167164</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name><surname>Francoz</surname><given-names>C</given-names></name><name><surname>Pri&#x000e9;</surname><given-names>D</given-names></name><name><surname>Abdelrazek</surname><given-names>W</given-names></name><name><surname>Moreau</surname><given-names>R</given-names></name><name><surname>Mandot</surname><given-names>A</given-names></name><name><surname>Belghiti</surname><given-names>J</given-names></name><etal/></person-group><article-title>Inaccuracies of creatinine and creatinine-based equations in candidates for liver transplantation with low creatinine: Impact on the model for end-stage liver disease score</article-title><source>Liver Transpl</source><year>2010</year><volume>16</volume><issue>10</issue><fpage>1169</fpage><lpage>1177</lpage><?supplied-pmid 20879015?><pub-id pub-id-type="pmid">20879015</pub-id>
</element-citation><mixed-citation id="mc-CR119" publication-type="journal">Francoz C, Pri&#x000e9; D, Abdelrazek W, Moreau R, Mandot A, Belghiti J, et al. Inaccuracies of creatinine and creatinine-based equations in candidates for liver transplantation with low creatinine: Impact on the model for end-stage liver disease score. Liver Transpl. 2010;16(10):1169&#x02013;77.<pub-id pub-id-type="pmid">20879015</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name><surname>Kawai</surname><given-names>M</given-names></name><name><surname>Harada</surname><given-names>M</given-names></name><name><surname>Motoike</surname><given-names>Y</given-names></name><name><surname>Koshikawa</surname><given-names>M</given-names></name><name><surname>Ichikawa</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>E</given-names></name><etal/></person-group><article-title>Impact of serum albumin levels on supratherapeutic PT-INR control and bleeding risk in atrial fibrillation patients on warfarin: a prospective cohort study</article-title><source>Int J Cardiol Heart Vasc</source><year>2019</year><volume>22</volume><fpage>111</fpage><lpage>116</lpage><?supplied-pmid 30705936?><pub-id pub-id-type="pmid">30705936</pub-id>
</element-citation><mixed-citation id="mc-CR120" publication-type="journal">Kawai M, Harada M, Motoike Y, Koshikawa M, Ichikawa T, Watanabe E, et al. Impact of serum albumin levels on supratherapeutic PT-INR control and bleeding risk in atrial fibrillation patients on warfarin: a prospective cohort study. Int J Cardiol Heart Vasc. 2019;22:111&#x02013;6.<pub-id pub-id-type="pmid">30705936</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR121"><label>121.</label><mixed-citation publication-type="other">George A, Badrinath P, Lacey P, Harwood C, Gray A, Turner P, et al. Use of System dynamics modelling for evidence-based decision making in public health practice. Systems. 2023;11(5).</mixed-citation></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name><surname>Schattenberg</surname><given-names>JM</given-names></name><name><surname>Chalasani</surname><given-names>N</given-names></name><name><surname>Alkhouri</surname><given-names>N</given-names></name></person-group><article-title>Artificial intelligence applications in hepatology</article-title><source>Clin Gastroenterol Hepatol</source><year>2023</year><volume>21</volume><issue>8</issue><fpage>2015</fpage><lpage>2025</lpage><?supplied-pmid 37088460?><pub-id pub-id-type="pmid">37088460</pub-id>
</element-citation><mixed-citation id="mc-CR122" publication-type="journal">Schattenberg JM, Chalasani N, Alkhouri N. Artificial intelligence applications in hepatology. Clin Gastroenterol Hepatol. 2023;21(8):2015&#x02013;25.<pub-id pub-id-type="pmid">37088460</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><mixed-citation publication-type="other">Guo C, Liu M, Lu M. A dynamic ensemble learning algorithm based on K-means for ICU mortality prediction. Appl Soft Comput. 2021;103.</mixed-citation></ref><ref id="CR124"><label>124.</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name><surname>Thorsen-Meyer</surname><given-names>H-C</given-names></name><name><surname>Nielsen</surname><given-names>AB</given-names></name><name><surname>Nielsen</surname><given-names>AP</given-names></name><name><surname>Kaas-Hansen</surname><given-names>BS</given-names></name><name><surname>Toft</surname><given-names>P</given-names></name><name><surname>Schierbeck</surname><given-names>J</given-names></name><etal/></person-group><article-title>Dynamic and explainable machine learning prediction of mortality in patients in the intensive care unit: a retrospective study of high-frequency data in electronic patient records</article-title><source>Lancet Digit Health</source><year>2020</year><volume>2</volume><issue>4</issue><fpage>e179</fpage><lpage>e191</lpage><?supplied-pmid 33328078?><pub-id pub-id-type="pmid">33328078</pub-id>
</element-citation><mixed-citation id="mc-CR124" publication-type="journal">Thorsen-Meyer H-C, Nielsen AB, Nielsen AP, Kaas-Hansen BS, Toft P, Schierbeck J, et al. Dynamic and explainable machine learning prediction of mortality in patients in the intensive care unit: a retrospective study of high-frequency data in electronic patient records. Lancet Digit Health. 2020;2(4):e179&#x02013;91.<pub-id pub-id-type="pmid">33328078</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>